var title_f8_29_8656="CT Bilateral traumatic SDH";
var content_f8_29_8656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non contrast head CT demonstrates a traumatic acute subdural hematoma over the left hemisphere and a smaller subacute subdural hematoma over the right hemisphere",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Xdm3t8x6+tJvb+8fzof77fWm0AO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dG9v7x/Om0UAO3t/eP50b2/vH86bRQA7e394/nRvb+8fzptFADt7f3j+dTwM2w/MevrVarFv8AcP1oAhf77fWm05/vt9abQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVi3+4frVerFv9w/WgCF/vt9abTn++31ptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFWLf7h+tV6sW/3D9aAIX++31ptOf77fWm0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFPijeWRY4lLuxwABkmup8NfD3xT4kmMekaLeTgdXEZ2j6npQBydFe9+Gv2YfGOpLFJq1xYaTG3LLI5lcc+i8Z/GvZ7D9mfwTHBZrqD393LCuJGWQRLKfUhRkfn+NAHw7RX6HWHwT+HdlD5aeF7KUYwWnLSN+ZNVb74DfDm7Yt/wj0cJxj9zM6j64zQB+fdFfYniT9ljRJkdvD2qXFtIekdz86/mP8ACvJfFf7PvibQYvMET3MQBLSwDzVA9wOR+VAHitFbepeGdUsAGkty6HunJH1HWsUjBweDQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFWLf7h+tV6sW/3D9aAIX++31ptOf77fWm0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTkRpHVEUszHAA6mgBtbvhDwprfi/Vk07w9p815csedg+WMf3mboo9zXrfwZ+A194uVL/XfMstLDDLEYeQeiD+vQe9fYPhDwrovhDSE03w9YRWdqvLbB8zn+8zdWPuaAPGvhJ+znp/hqVNR8V3Kapf7flto1xBGfc9WP5Cve7W2gtIEgtYY4YUGFSNQqj8BUtFABRQSAMk4FR+fFnHmx59NwoAkooByOOlIzKoyzAfU0ALRSKyt91gfoaWgDk/GHgDQPFUJ+32axXI+5cwAJIp/r+NfH3xw+DWt+C3fU4IhfaKGw13CvzJ6eYvb69K+7aZNHHNE8UyLJG4KsjDIYHqCO4oA/K6ivrT40/s5200s2ueB1+zpgvcaaoyPdovT/AHfy9K+W9V0ufTpP3gLREkB8d/Q+hoAz6KKKACiiigAooooAKltoJrmdILaKSaaQ7UjjUszH0AHWvUPgJ8J5viXrkrXcslroNkVN1Mg+eQnpGhIxk45J6D14r7S0Xwz4P8A6fbrYWGnaXEhEaTuoDsxGOZD8xJA5JNAHx54M/Z28c+IoknvLWLRLZhkNfkrIeOP3YBYfjiuD+IPgXXfAOsLpviO2WKWRPMikjcOkq9MqR78c4NfpVG6yIrxsrowyGU5BFfCf7S3xQtfiF4itLPSIcaTpDSpDcOCHnZtoZsHovyDA69SeuAAeM0UUUAFFFFABRRRQAVYt/uH61Xqxb/cP1oAhf77fWm05/vt9abQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfR/wCy/wDCWPXmPiTXoCbBDi3Q/wAZ715D8K/At/8AEHxdbaPYBkh/1l1cbciGIHlj79gO5r9EfDmi2fh7Q7LSdMiEVpaRiKNe+B3PuepoA0Io0hiSOJFSNBtVVGAB6AU6iigAqtqV9b6bYzXl5II4Il3MxqwzBVLMQFHJJ7V89fHLx418raRpz4tVkG9x/HQBj+PfiXqeuz3EenzvFp+7asacYHv6155fazqiBJRNIoJxkE81p+EtPmvraZlh+6SxbHam31mxYxjtxt9DQB0HgP4g6k+m39o97P50KF0BcnHHavP77xXrOoXTyzX9067vlVpGI4/GjwvHIuuXyMpA8mRSR34rH0qymvkcjChAQOfegD0PwZ4/1DRr6Cb7RK4z8y78jHevrbQtUg1nSre/tGDRTKGHt7V8MSWcmnKkk/BJG1a+sPgXcK/guKFWYhG3DPoaAPRqKKKACvmL9pb4fxaakuvabaj+zbtsXkUa/wCqlJ4cegP8/rX07VXVLC21TTrixvolmtbhDHIjdCDQB+Xd1CYJmUg7c/KSOoqGva/jT8OJfC8t1AEaUwvvt5MffhPT/A+4rxSgAooooAKKKKAPqL4W/FLw/wCBP2dbhdKu7P8A4SyKWUmylzukmeTCyY/iUR7SccfJjrVT4N+Odf8Ai54lfwt45aTVNPeF7hbiCFIWtWUcMSigbTnbz3Ir5w0+dLW+t7iWCO5jikV2hlztkAOSpx2PSvb7D9om50PT7iDwn4L8OaJLMQzSW0RAJBHVRjPHHWgD6j8Z+KND+FHgLzZ5l22sJjsraSTMlxJ/Co7nnqccDmvzru52ubqaeT78rl2+pOa0/FfifWfFuryan4hv5r28fjfIcBR/dVRwo9gKxqACiiigAooooAKKKKACrFv9w/Wq9WLf7h+tAEL/AH2+tNpz/fb602gAooooAKKKKACiiigAooooAKKKKACiiigAqa0t5bu6htraNpZ5nEcaKMlmJwAPxqGvo/8AZC+HZ1XW5PGGqQZsdPYx2QccST92H+6P1PtQB798DPhvbfDrwjHbsqvrF2Flvpu+7H3B/sr0+uTXo9FFABSMQqlmICgZJPalJwMnpXgHx0+LcVrby6FoDh3k/d3E4PY9l/xoAf8AFb4to11caN4fkUpF/rbkHIYjsPavIpphfOJLvnzDvGe5qjHYfJFIFDMw3MDyTmpdT3QoF27mXByP4RQB7n4Y0i1tvCSSfIks0fzDPLV5l4mhNlqwMWCrABvY07UdeuPsFs9tM4jjUKMGs2/umvIY4lViSQSx6k5oAht7GQ6wWjUxl4ZC4Hrjis3wZYfZ7eeW4QuS52g9+a2bS6z4pjiZyEit3LAdziqHh2RntmSVJCBIWVe2M0AaGoxpcRBXjX73PHIr2j4RaxFYWgtX2qAvzLnpXjzktG/Kh87wcdBnpWlZ+I10O8ghAV5pnUe4HvQB9UWt7FcuViyQBkmrNcD4Z1qC3s45ZJA5KnIU11Wi6xDqnmCIgOmPlzzQBqUUUUAePftRaJPf/DW61KyGZ9O/ePgZJiPDflwfwNfBzqVxkdRkV+pOpWUOo6ddWV0oeC4iaKRSM5Vhg/zr84viP4QvPBvie+0e+GGtm+RuzoeVYexGKAORooooAKKKKACiiigAooooAKKKKACiiigAooooAKsW/wBw/Wq9WLf7h+tAEL/fb602nP8Afb602gAooooAKKUAk4HJpWUqxVgQwOCDwQaAG0UUUAFFFFABRRRQAUUUUAdP8OfBuo+OvFdnouloQZWBmmIysMf8Tt9B+Zr9F/CmgWHhbw7YaLpMXl2dnGI0HdvVj6knJJ9TXkv7KPglPDngT+17iMf2jqp3k45WMfdX+Zr3CgAoorgfi948g8GaA/kyKdVuFKwJ1Kf7ZHtQBT+KXxO0Twzb3OmG6EmpyIU8uM58skd/evk64xqN41xc5JdsAj+H0rM1drie7nvLqRp5JD5hdmyxYnvV/SgRGrygsTywH8NAHXRXEKlMkLkBR+Ap7eVNbyLIA68lWFY1jZpcPE0juTHxj/GtbEcG/fwAoHB70ARyxtbKsCEFWAKqe1ToSiF0UAqOSfWmRx75o7gt8pyoB5wPWrtiyZnW4OBGNw3dMUAcbpN7P/wkt685XfJE3HoMV1mhlFsVZSFJGdo6n1ridMuPtPiS/ZRk7HwR24rV8NtdPbbHJCseD3FAHRwTLDIGX5lAJwTkVzemO2p+JJJ7kk+SOM9M5roLllJj8tFVdu0Kvf8AGsjSmFrqV3kBQfmGDQB1F/rtxp0LMkpAiAGM9a7T4deM3juEnkKoS/IbjcD1Fea7VlwJVJEpDmQnoPTFVZTLbSloGPD8DNAH2vbTR3NvHNC26ORQyn2NSV5L8DPGK6pZvo95MGu4hvjyeSvcf1r1qgAr52/bB8J/bPDtl4ltosyWTfZ7kgc+W33T+Dcf8Cr6JrG8ZaDb+J/CuqaLdj91ewNFn+6SOD+BwfwoA/MeVDHIynsaZW14o006Xem1dXWeBmt5g4wRIhwaxaACiiigAooooAKKKKACiiigAorqfhv4K1Hx/wCKYdD0hoY55EeVpZjhI0UZJOOeuBwD1rC1jTbrR9VvNN1CIxXlpK0MqH+FlOD/ACoAp0UUUAFWLf7h+tV6sW/3D9aAIX++31ptOf77fWm0AFFFFAHb/BKNJPi34SSRFdDqMWVYZB+auq/av0u2034yai1qpX7ZBFdSDAA3kYJGB325PuSa5f4Hf8lf8I/9hGL+ddx+2GjL8X8kEBtPgIPry1AHh1FFFABRRRQAUUUUAFdv8HfCMvjPx3p+nKmbdXEk7EZAUHvXEV9hfsbeGvsWh6jrUyqZLoqqkjkD0z9OfxoA+idOsoNOsLeztECQQII0X0AqzRXP+OfFFp4S0CbUbsGRh8sUS9ZHxwKAK/xC8ZWHgvQ5b69YPOVPkQA/NI3+Hqa+MNb1++8Va1Nq+qyyySysTtIwEHYD2q5468U6r4p1Ca/1R3yz/Kn8KL2UD0qxoduqW6+fE20jPzdCfagDn7ORLqcwtw44JxxV6OYQTLGU+XdgtjjFXL3SGh3XdmuGYktGKZYQJqKuIcqw6r/PNAGnp9uqlZU4Rsk89aszIpk2znau0AnrxVSyje0BhJ/duMqAe9OnkA8skZAGOvX60ATTOhh8q3P7sEfMRzUjBWV4y+WdOWz0FRAIUJUghiOF7Cub1tLrM5hV4wzFAQe1AFj4bQwXfjeZODGqSHOODxW3bIYFk+VVGSBj0z1rA+DkRh8XXNuSd3kOMj1xWzaTN5UiTk7/ADGUqDnODxQBO8u6H90R8vUmq9mIkheZsNITwR2qU/uVbdwB1wMnmq0WIiYFBEbt5hY9/YUASXd01skZ2GSZ2G1T3FPuYLm7hWRwEL5LY65qzAFyWlG4ocoD24qOV3kjHlDA3BmyaAK2iXd34X1+31KwkbzonB2H26/hX2P4V1u38Q6DaalakbZkBZQfuN3H518e3eZLaVF5bGM47V6N8DvGEXh+f+y7qYtaTYLE/wDLNvWgD6SopFYMoZSCpGQR3paAPjf9q/wONP8AE91rlqAkF4i3BXoDJna/4nhvxr5zr76/aW8Py6z8PWntkLy2Um5gBn92w2v+Xyn8K+CriF7eeSGVSskbFWHoRQBFRRRQAUUUUAFFFFABRRRQB9H/ALEkUb+NPEErRq0iWChWI5XMgzg9s4ryb42/8ld8X/8AYTm/9CNeufsRf8jf4j/68U/9GCvI/jb/AMld8X/9hOb/ANCNAHE0UUUAFWLf7h+tV6sW/wBw/WgCF/vt9abTn++31ptABRRRQB23wTkWH4t+EnkOFGpQ5P1bFesfttoo8b6A4ADNp5BPriRq8N8DytD400CSM4dL+Ag/9tFr3T9tz/kdPD3/AGD2/wDRjUAfN9FFFABRRRQAUUUUAaPh/T31PVre1QDDNls9No61+ivwp0xdK8DabGsQiaRPNZQuMZ6fpivjb4F+G21C/jnkXH2mVYoyRnjPP6/yr70hjWGGOKMBURQqgdgOKAH189ftBaw+oeIbTSreUCGzXdIBzl26/piveNa1GDSNJu7+7cJBbxtIxJx0HSvjS619tY1HUL+6GZZ3ZkIPqetAGJcKqanNHJkxpjAPNXnmKQRGN888ZPAqNYBOnzMfPbk+4qGUC3kUFAwLZwe1AGxaSM0SvIxLLglR6VRvrRtP1D7VppYQycyRjvntV7cHTZHt3MADzinpu850LDe4GAfWgCvDcpcIZDGQ64+UdBUaOZio24K/NjHWnFgiy7VAnPDEHgj2FNtt+TI8ZAwBj0FAEkO7yeDjuAOvWq+qAl3ZmzHnIA7Gm3rOjMEG07sgjoR6VBNbyTxyvI2zK4XHOKAD4bypB4l1G7OQUt35PYmtFLZIWa4Vyytkgn196wNItZbPT9Ul/icAYzz16Vr2AmktVWYkKwyADQBcuNjvtR8BgMn39KcyLEzbsllAGTzxUV8iqqOpHyLkrjj/APXUE8jYUurbDztBz1oAmjctudsFfr+lWIZUe3Y+VwV6elUoGxFIsIDAg8kdKdZXcXlvbSkK+PvE4oAml/c2/kxkeY/zbvf0FN0K0NnqP2y4ZiwIO0dAasyCNlRnMbfL/AecVYgxKhBBCEdB3PagD6Z+GmsnUtFSOSQOUA2c849K7GvDPhReRxjZCWWQYyPSvabKWSQOswG5emO4oAmuIY7iCSGdA8UilGU9CD1Ffnz8ffCx8L+PruFQPKmJZce3/wBYg1+hVfM37YHhhbmzg1iJGMyx5J/3Tz/46f0oA+RKKKKACiiigAooooAKKKKAPpL9iL/kb/Ef/Xin/owV5F8aXWT4teLmQgqdTn5H++a9d/Yi/wCRv8R/9eKf+jBXhnxAn+0+O/EU2c79QuDn/to1AGBRRRQAVYt/uH61Xqxb/cP1oAhf77fWm05/vt9abQAUUUUAbHg3/kb9D/6/oP8A0YtfRX7cOnBNR8K6kG+aWKe3K/7pVgf/AB8180aVeNp+qWd6gDNbTJMAe5Vgf6V9Rftty+dpPgmXGN7XLY9MrCaAPlKiiigAooooAKdGpd1UdWOKbViyikluUWFSXz2GaAPqz9mjTUvdXg8jJtdNj3MexfGB+pzX1BXln7OnhuPQvAUNwFYS32JGLDkgcD+tep0AeTftH6k1v4Kj09CQb6XaxHZV5P8ASvk+2uUsrxYpDmIdia+oPj1597cQW8KDZbx7ix55PavmHxTawWzhACZCNwK9jQB1toIpLbcAMYxkHmopY42DMp3FR1PWuK0S5uom2mQ+W3O1jXoMBiFnMwBwVBU+lAGSJwhweG4I9Ks27SMxPIIOC/8AQVXltwXL53Oy444Aq4EYrEkThQD3GfrQBXWQqz4XkdWPUGp4MtCWbG7qRnG6o7qMhVeMEg8c+o70kCERhp/lI7DnfQBYuYPMhkAXYMB/oaSyjLKduCD1z0piztcxeWpHlkFVB6tU2mxgiIOygoMBRxQAxLZfs7SHkFsODU89usUY8jOwDBJHT6UXyNHp/mDO0SBMdMGluJm8p8dAMYXpz3oAqELFKnmnjp9feoHjkFxtc4XOQx9KmkaJkMiE5T5WB9aZcbmaEtJuUjjI7elAE9pGF80K48vOAeuTVO98p2UMAXXJVjwPeriZNvsUiMq/Jpv9mW/35nMjt3B+6M0AUbHiUBcnbggKODWuY7/DPHIgRVzgDPNNgiVX8i3VQiEgMetWow0cDW8R3g+nb1oAu+AvEc9hrUa35winbkcV9R+Hr6O/SOdZA2YwFHevlPTNPD3rDy/mXksegr6O8EaRM1hZzuxREVcc9aAO6ryX9pezabwAlwnAguFVz/sOCp/XFetVy/xQ0p9a+H+uWMSCSZ7ZmjUjOWX5hj34oA/Ni6iMFxLEedjFc1FW94w064sdSSS4i8s3EYkC+nY/yrBoAKKKKACiiigAooooA+kv2Iv+Rv8AEf8A14p/6MFeB+LP+Rq1n/r9m/8AQzX0H+xBAT4j8Tz/AMK2kSfm5P8ASvnzxZ/yNWs/9fs3/oZoAyaKKKACrFv9w/Wq9WLf7h+tAEL/AH2+tNpz/fb602gAooooAK+q/wBtCNz4b8DSBTsXz1J9CUix/I18qV9e/tV3sOrfAvwhqcCjZc3dtNGT1CvbSNj+X5UAfIVFFFABRRRQAV1fw80+a/8AE1hbQgl55AoGOvOBXKgZIA717/8AsuaQbn4gQI6K0duhlYkZ6dP1xQB9j6JYrpmkWdjH92CJY8+pA5P51doooA8U+KNy8+p3i7WMYbyx+AxXi91YWo1BldFdl6Fua9a+Id2bi+unUeWhYk45zXjcF3EuszbGYr0Xd60AGo6Ta3cUwEW1lOFZOOawzfahpoNvMu9CcZHt6108kksgO3apzz71CXikR4blNxJ6+lAHPSvdXUqtFIijbj0yavWEeqovmMocKOefXtWgtlbwgYA+UZy3b6U+W6eJSivyeMdj70AJO8aQ7nX5yvTPANUIN0hcRsCuM7sd/SntiSSPzZCOCTkUqbjlV+RWPOfSgBIVa3lRRsYlgCSenrV2EBJSACSvzLkZqnIywtGYwB6lucVbLYTzm8wHtjvQBODLeWrYX92JctngcVDLKS0jHITcBwOQKvWZdNEAdT88pwc9qzb0gyxPkjuQO/pQBHMQAyzAlDyAvf3qG4XkAblIxgk9vWpW2SIpBbc33ie1RMFWZsnzCCMDOBigCxvIkmIG7CghcZP1p5PlxMCvOAGz1OaSNiS+35WPBPUj2qwWkWRh5W5ccse1AAfljby85K7asQRRWyo/LBjk4NU/tJt7hA0TMMcGmQ6palwpcLIhxgjGSfSgDqvDDeddHYh+c4+boa+i9H1JYNPtYAu0CMA47GvDvh5pZnkEkZYjPpmvY72IxQQFG2sAA64/WgDs1+6M9cUpGQR61W01mayi3NuYDBPrVmgD83fiLaXtt4n1/Tr9nebTbyRAX6lN2B+m0/jXG17t+1PoP9jfF2e5Xi31u1Wbns4+Q/qoP414UQQSDwRQAlFFFABRRRQAUUUUAfWX7DiL9h8XvgbvMtRn2xJXzH4s/wCRq1n/AK/Zv/QzX0t+xY7Q+HfG8yg/IYGB9wkp/wAK+WLmZri4lmkOXkcux9yc0ARUUUUAFWLf7h+tV6sW/wBw/WgCF/vt9abTn++31ptABRRRQAV9b/GrTWvf2T/B1yrhRYW+nXDA/wAQMHl4/OQH8K+SK+xfiZcRXP7HWkyQOHQWGnRkj+8rRqw/Agj8KAPjqiiigAooooA0/DliNS1u1tWJCO2WwOcAEn+VfZX7LXhSHSdL1TV1BL3LiJN33go5P9Pyr5U+FVu8/ipWRA7RwuwX1J4/rX3r8K9LGleCLCHyzG8gaZ1J6Fj/AIYoA62qes3C2umXErkhQh6Vcrk/H0sv2IRwtkDl16Aj3oA8P8fX62+n3Bj/AHa4JBbqRXh9o101758OVRu5P8q9n8f3EBtPKuNjSSZJUHpXntnFbNL7Y6Z6j2oASykuiWLsjL/Fg1PMGRC0Tgu3LnHT2q8LWKFR5YHPOKZbojLJt+ZhyyigDPE3nBGwRk4OanuUbzIyY1YkcDOCKWS3aVwsK/PnIBGKYzeW8pOVlU4O4dvSgBML5K+Yu4k/Ko7UiAc71BLknHTntioN2DHv3AA7iAenpVuORUmQEklMknr+VAEGP3xzym7JHvWnbmWS3b5AU3dSao+WsSMxJx1A7nNXcGK0DRqS5GFT3oAu6n5tto9vHEwz5hc4HAHpWberu8ogDzJF4PpWumV0u3baWllzlW6DFZVzmMuyghtud2OhHagCp/rCASQnsKJv9bADjPRm9R6UxXBK4fa7jeQefwp8aKlw5L5IXO31oA0NP8y3M4ZEZCwKEjNPEikMjkgsD07mqiOGDBZNqKMEMORmlBV28tGJVRgHHegC3HJEQqTEblXG3uarano0N+kJt4gkxIY7eW61YtooUIJXJIwx/wAK7D4V2Uep+IWWSFlWPAVj93PpQB6Z8JdEl0/QYpLhTuXkZ6nNdRrt/sV1VVHybQWGSa3YI44bVtiZwMEdAK5fXLWZ5Q8MBKZxkDoKANvwrqIv7Fl8sxtC2wg9/etuub8HWM1mlyZsneRz2NdJQB83/tr6V5vhXQNYjQmS0vGhZwOiuuefxQfnXx/MD5hLDBb5vzr9Cv2htC/t/wCEHiOBV3S28H2yPnHMR3n/AMdDV+fN2oCwMP4owT+ZH9KAK9FFFABRRRQAUUUUAfYv7IFvGnwg8S3Kr+9kvpkY+oWCMj/0I18dV9kfskyJD8EfEcsrBY0v7lmY9gLeLJr43oAKKKKACrFv9w/Wq9WLf7h+tAEL/fb602nP99vrTaACiiigAr68h09NR/YoRJGK+TavcKfdLpmA/SvkOvrr4fXF1rP7HmtWscO+S0guoI1QcsobzCfr8x/KgD5FooooAKKKKANzwxqUmkm7vIM+YiqBg471+jXgGeS68D+H7ifHmy2EDvj1MYJr804pQljcIBy7Ln6DNfpv4WgW18M6RBH9yK0hQfQIBQBpOwRGY9AMmvF/iB4zSSSSKEkAnAPYV61r03kaNeyZI2xNjHrivljXDOZG3RyFyxwuM5oAxdVjhuryWeWQyM3TnpWTJYrBhrZznOc9QKvBCwlDxlGDYx3qIRmEARkHJ+6aAJrMyrv3kMAMF8dT6VT1C2lab7Ra/K4+VlXjdWhKjopZlCqWGBnim7S3leWWLAHJHFAGf9pu0dWCnIO05PU1PvkuEZLuNVdRkkd6m8wq8QCbjgjc3r7VDeuEhmJKnac8UAQTEqwCEndtAU9TSyFnSV4yAwwAvvUSoVkgd/mGQSc9BVqFA8j9D8wKg9MetADY4JWLE4MjJn5ulaVurG2Xadxj7/zpsbJHNhm3SdxnIp0m4WxKsNrE8r6UAaV7Ctva2jI27d823p9aynGZnRmAViQMnpWlqqr5dkzPhVtxhP7v1rPEXmRqQA3PagDMkRY7tmByiDAzxn3pblgNjgAhlw2Pen3GHnlTGG6kYqI4CDDs3IXGOlADgS6bAhUcck9cVowCQJg434BK5xVa5P2SAgDfL0Rc96dbfu8Xd4MSsNoQdqALiSKi+UrttzuUAZOa9d+C1qHu2mRd0edxwOc15Dp8DT3CbF3SFgEx6E96+qPAulQ6XoMUaIokYbm470Aby4O9GGB2BPUUqgBCpAAI5HakkJygGPm6+oFSEErgYGR3oASGJIkCoMD61JQBxiigCK6gjurWa3nRXhlQxurDIZSMEEV+bPi/Q30k3MDRspsb+eyJx1AY7f5V+ldfGH7TGkz2Os+JTFBm1kvYLppR2Z4zkfnQB89UUUUAFFFFABRRRQB9g/CWzis/2Q/EM8AKy3dlqU8pz1cK6A/98otfH1fXmkm98P8A7Fd1JhUmntJMZ5/dT3G0/iUkNfIdABRRRQAVYt/uH61Xqxb/AHD9aAIX++31ptOf77fWm0AFFFFABX1/+yvJc638EfFOiQRxiVZLiCFicbmlhGM+nNfIFfU37D+qEXPinSXuVClIbqKA4yeWV3H/AJDB+ooA+W3Uo7K3BU4NNroPiBpI0Hxz4g0pI5Y4rS+miiWX73lhzsJ9crg575rn6ACiiigBcnGK/UXQv+QHp3/XtH/6CK/LpQWOAMmv0v8AhpevqPw78MXkhy8+m28jHOeTGtAGvrOwaVdGXGwRknNePzSQPDPJFahmXnJHNezX8YmsZ4yMhkIx+FeNlBDvk3srFjlT1P0oA881aX7RPO0lsI1A7LgmuOuHMLNHEr7jjnvXdeLxKjuxGwOflB61wtzdxW115Sgvc4y5Hb2oAesymPMp5UcbuKkSYzFFijzGAPu+gqdgrW4aVeXHSj5QWSABcqA7D+lAFW+mVHRMbSecHtVO6QuAS2AfnKjvV2URqSZVLZ/ib0qvPEipFJFjyicEigBgAkOVPzIRkegqzHuM9w0eFKopDHpioSokbYAv54qxbxmJ2XIk3AAZ55oAc8iecqBUDtg7h2ptxKiQlEcbf4ee9AGS4bkM23r3oNqVlDKNyrgjjrQBpXiSLbxiXa26FSdx6VXhCLEkb5XaxLAHj2q5rkbi4YHJBhTC+hqk6b2XauScFqAKNyQD8jHbtLA/zplsQpzGBtchjntVq/2JNK4TaFA5HQ1nhmk3qvHAwR/KgDRmZUVlCgyE5DEfdNIkTzbnZhuBwB1BqlbO0bySbNw4BHrWssy+aFAwBzj0BoAv+EUE/iOzVgEjVgWfsK+rNJdvsETLnA4IzkEetfJunsYL8iOQ5YrjHevqDwaxl0GLY29wMHPB5oA6PAIJGNxHJFOByeOo600DPBHbmkJ2FAoypOCc9KAJKKa0iruyegz0pIm3xhgc570APr5m/age283W7ElhcXFhFc4HT5GOD/47X0zXxf8AtZX8kHxWuU3ssZ0eOLA6Eszf40AfPdFFFABRRRQAUUVa0uzl1DU7Oyt4nlmuJkhSNBlnZmAAHuSaAPrL4sC90D9knQNPZkV5orOCfb8wKEeZgH6qtfIdfXH7ZMkGleBfCmhWlwyIsx2wFiS8ccYUE+uMj86+R6ACiiigAqxb/cP1qvVi3+4frQBC/wB9vrTac/32+tNoAKKKKACvZP2TtcGj/GGyhkeNItSt5bJi6kkkgOoGOhLIo5968brX8JazJ4e8T6Vq8JkDWVzHPiNtrEKwJAPuMj8aAPTf2sNFbSvjBfXAWURalDFdKz4wTt2HHsCleN19ZftmaJHqnhzwz4u05UlhTNvLNHlt0UgDxNkcbQQ3PcuK+TaACiiigCW2IFxHvJVc4JHXFffX7MN+t98F9DQOXktGmtpCexWViB/3yy18A19Z/sW+I1aHXfD0rqHO3UIRu6g/JIAPYhT/AMCoA+oK8k8XWPkeIphI5CD5xnptPSvW64X4oWK/Y49RwWMf7sgfmKAPJfiJKRp0bRx5dxnpyK8w0+3CTTyuuXkIZmPU+1e06gi6no7xrH86rw2Oc15a8DQMVnjy4JAAOPzoArySeZjaqpg8DPSnREsGjwGP3mxxgVGybWbI4/hUd6S4ngtkkJyrMuSaAI9VhVrWJZW2B26A9qVEjEUHkqVBGAM8L7mqTw3WriFiRHGmDzxxWptSEeWrA44Hv9KAKEy7ZxjaVY9R3NWbRjHbNJIQoV8ZBqFInLorjCh+T2pG2zRyRvyCxC44AxQA62mjeVTnh2JyRwBVx3YhvKIPzYA749aj2pDaZVAMAHntQLpIpYQzLjb83uTQBsa9I8kwG7AEanb+FZ9uy71JDbWGCOhFW9cMY1FGjkARY1OAevFZxd0ywOWc5+goArXp8p3G8tGvzVSON7EA7WGR6DNWrnLltxVdvUD+LNQ2kXmSxrLxwc4PBoAv2USrG27YxbvSwPB+8jBYE8fMO9MiYJLsUgIGwM+tWoxueVJkDY5xQAZQNGocs6sDkjGa+lPhfNJc6DGrMQ4GGIHTHSvmjaFlAbcqKckivdvg9qWLeOEEtzhi3HHrQB6wcRDueeT1zUM8refEgjJ759KWMh2ZWY7mz07Cql2GYKqOd6t96gCxfZCckgNxxU9qNtvGOeneog0uyMBQ3OGJ/nVqgAr4N/aq1Yah8YdWt4mBitUhhPH8QQE/qTX3izBVLHoBk1+aHxH1c6/4817VCci6vJHU/wCzuIX9AKAObooooAKKKKACvSP2eNDOvfGHw5CUd4rWf7bIUYKVEXzqee24KCPQ15vX0z+xNoHn69r+vSxqUtIUtYmZDne53Eq3TgJgj/aFAGX+2lrQvPiDpWkxyRPHp9jvYL95JJWJKt/wFYyP973r56rufjdrjeIvir4kvyzsn2poI96BSEj+QDA9AtcNQAUUUUAFWLf7h+tV6sW/3D9aAIX++31ptOf77fWm0AFFFFABRRRQB9n/AA/QfFX9mCbQywm1Kzt2s4wWUkSxfNCOwXICDntzXxiRg19GfsY+Kxp3izU/Dd1Ntg1OITW6sxwJo+oUdAWQnJ6nYorgf2jvCn/CKfFbVookZbS/P2+DIwMSElgPYNuH4UAeYUUUUAFdt8IfFp8F+PNH1ksVhgn2XA/vQP8AK/5A5+oriamtnWOdGcZTOGHqO9AH6mRSJLGkkbBo3AZWHQg9DVbV7CLU9OntJwCkq4+h7GvLP2ZfGf8Awk/gBNOupA2paKVtJMnl4sfun/FRj/gJr16gDw/TYG0/Vrixu0YNkpjPQ+tcN43sRY6jM8SdeAete1/ErSpVeHV7RRiL5bjHUL2b+leYeOgktmrqWdSu7eozk+9AHmN5cG33St26AVUt/wDiYymZgQHOApHYVpyRiRGZ1IUcYNZ8FvJZvkMXhfndjp+NAF7IWMqflLenYCmhzJblY1PmluC3RR61NuWSQlQuQuOelRDOZAABjgEHqcUARQgqsoYbnT7nvVa2JkkwVCtnv2NWUulEjGIExoME5/Oo1VQzlEbaeQaAE1ZJ54fKgYKrYQn2qBNFkDwqZgwPHuauucEIrcYzgd6sxgvcwbT8qMP1oA0NYgjilIZV+SNE5HtWcqCRflcbScE/4UanqDHVbuKUZw4APbAFZ25oY4zlnDPkr/doAluQARxwe/c0x3ZUKrGucbeRz9afO7NMgYbmZsY9KsukaEKeNi8++aAIo4i8mCRkYYtirUSOsrktlcgEVCu/yGZvlUNk8djTvtSsd20gZ2t/jQA5Ina4ZFZjk9z2r3L4TaYqWiFmJ3DDN3rx3RUFzqESbRk8EjrX0B4Ntmt7ImR/lfaoxxigDrPs7OiyBgsn3QS2CanijMKsspBLYOev4VCreZLgEuVOSSOmKkmMjBBGGUucUAWoGZznc20cYI71PTYk2Rquc4p1AHFfGXxKPCfw013VAwWdbcwwZOMyP8q49+c/hX5xOxdizdScmvp/9s/xktxc6Z4Us5gywMbq7Cn+PGEU/QEn8favl6gAooooAKKKKACvtj4aw/8ACr/2Y7vWJE8u+mtZdRIdGOZpQEh3Lnp/qwcY45r5L+HXhmbxh420jQoNwF3OqyuoyY4wcu3pwoPXvivpX9svxHb6Z4Z0Pwfp/lxeeRcyQRgARwR/LGMdgTnGP7hoA+SGYsxZiSxOSSckmm0UUAFFFFABVi3+4frVerFv9w/WgCF/vt9abTn++31ptABRRRQAUUUUAa3hTXbvwz4k03WtPK/arGdZkDdGweVPsRkH619b/tOeH4PH3wp0rxjoYM7WEYu12jJa2kA3ggHqpCk9cYb3r4yr66/Y88bx6nod/wCCdVdZJLZWmtFkORJC3348H0Jzj0Y8ACgD5ForuvjV4MbwL8Q9U0lI3SxZ/Psy2cNC3K4PfHK/Va4WgAooooA9O+Bfj/8A4QXxpZahMzCwkH2S/Qc7oSRhwPVDg/Sv0EikSaJJYnV43UMrKcgg9CK/LCGRopFdeoP519lfsq/E1NZ0weEtVnJvbNN1i8jZaWEdY/qnb/Z+lAH0JNEk0TxSqHjdSrKehB7V5N4k8PLpNw9tKhexnP8Ao74ztP8AdNeuVW1Gxg1G0e3ukDxt+h7EUAfJ3iTS5rS8m83aICcj2xWPku2I2ygGdvYe9dV8YbbVLPXDp32ZyR8yOB8sieorjdLiubVZo7yAq7jCmgCJQhlAV2GMsR2P1ov52ht4kjUCWY4XjoPWrbQgs5iGABgkjrVS7dRqkDyZKghRkYGfagCYQi2tYYCQ5OdxHU1NCyqZHYll2ALgZOaiuZsMu3gs/OD2p8f7uRFLkITtYY7UAVwwaTzFVh6Y6Cr+nyL5oCKCNwy2Ov0rAvZLq3uGxGfJYEgL+lXvDl/KdQjtn4wemMZNAEtzB/pcs7YHmSnnPYVKx3mIyKNwB+UdOKkuHUsQQpAckn3FUmuluIUjXAIJB9TQAtxlpvMYjyxjtVh3WS33SZ56eo9KgeNTFtcY+YA5p0jMbJwWOU4FADpZB5MwckpgDk9DVC5mbYEjOWA+bjrUpErwybSC2N2G9KpQ2lzcRlgGXPHpj/61AHafDdXutet1Z8MeCuMivpuGxSKy+VhvjAbA/ir5T8BX66J4rsZLgOke4KzHpX1iVWSKGaABo5B8rZ4IPegCJDJbzxvIFXzBjb3ya2raPais6gSEc4qO3tgAjzANIBwatUAFcn8UvGlp4C8F3+uXexpY12W0LH/XTH7i/TPJ9ga6yvh39qj4hW3jLxRbafot/wDaNH0zcmEPySTZ+Zx2IAwoP1x1oA8e1/V7zXdWudS1KVpry4cySuf4mJyf1PSs6iigAooooAKKK3/Avhi98Y+K9O0LTgfOu5QpcLuEadWc+wGTQB9D/sX+DQZNV8Y3qELGDZWeRwTwZH6f7qgg92rxD4zeMH8cfETVdXD7rTzDBaDJIEKHCkZ6Z+99Wr6h+P8Ardj8Lvg1Z+FNAJhmvojYW69WEIH75yfU7sH3f8viegAooooAKKKKACrFv9w/Wq9WLf7h+tAEL/fb602nP99vrTaACiiigAooooAK2/BniS/8I+J9P1zSZNl1aSBwDna6/wASNjqpGQfrWJRQB9zfF7wzYfGn4TWWueGgk2pQxG6sDnLHj95AecBiVxz/ABKPrXw26NG7I6lXU4ZSMEH0NfQ37JnxMGga2fCWsThdM1KTdaO5AENwR0yTwrYAx/ex6mrH7V/wqbR9Sk8ZaDbt/Zl22dQjQDbbykgBwB/C5PPo3+8AAD5vooooAKvaNql5o+pW9/ptxJbXdvIJYpYzhkYdCP8APNUaKAP0N+CPxOsfiR4ZSXfHFrdqoW+tc4Ib++o7o36dK9Hr8yPBfijVPB/iK11nRLkwXcB+qyL3Rh3U96/QH4V/EbR/iJoCXumyrHexqBd2TH54H7/VfRu/14oA6bWNHstYhVL6BXKZKP8AxIfY1498RvAs1opmtEMsAHysByCfWvcabLGksbJIodGGCCMg0AfHdxAbWVreXsMZNZ9/ahreOJwXfOVx2NfQ/ij4T2Wo3Ml1YzFJWyfLf7v4EV5nrXgbVtE8x57WVo1G0MgyPzoA8oZTYavbJJN5hznBGcGtuQK10SrA5HbsaS60Waa9e5nQx+X0BHU0qW7W6LvU7zzkjqKAHy4G4bt3H3cVd0+yZ2eWMK0vlsc4+6cVXyJDG0X3hwVrofDUXlC7+04MboY1HcE96AOI/sqVTEjXLFSDI3qasLb4tYpIQplXoKv3CCO4fdy8QK1ThGAyGQBV5BPr2oAZFI5MyzxjOMk9s1U1OV0sVWE/vG6AirlyrMFEZLblyxFKI1kjKMF3xnAwaAIrBXezDOhEgGCemasgxCIJJIyyKOc8Amo7EtJ3zgZx6muk0zwPrPiWMw6faOyP1lYbVX8TQBBpFtDfXcUYcSOQNqqM5NfTngewurLw/bxaiP3qjhT1A7VyXwr+FVv4PP2vULkXt+R8oA+SL6Z6n3r0+gAooryf47fF6w+HOkta2bR3XiS4T/R7bORED/y0k9B6Dv8ATJoA5P8Aak+LUXh7R5/CehThtavY9l1Ih/49YWHI/wB9genYc9xXxfVrU7+61TUbm/1Cd7i8uZGlllc5Z2JySaq0AFFFFABRRRQAV9qfsreAYfB/g6fxbrgS2v8AUoN4eZgogtOGBJJwA2Axz2C14X+zf8Mn8eeLlvNTt2Ph3TiJLhmU7Z3/AIYQffqfYe4r1r9rz4krYaevgjR5MXNyok1FhkeXFwUjHu3U+gA9eADwD40eO5viD47vdVOVsIz9nsYyMFYFJ2k+5yWPoWxXCUUUAFFFFABRRRQAVYt/uH61Xqxb/cP1oAhf77fWm05/vt9abQAUUUUAFFFFABRRRQAqkqQQcEHINfcHwB+I1j8UfBs/hrxUEu9ZgtzHdxzJ8t3BnAf68gN78jrx8PVqeGte1Lwzrdrq+iXUlrf2zbo5E/UEdCCOCDwRQB2/xx+F1/8ADjxLIojaXQbuRmsbkcjb18tvR1H5jn1A80r778O6x4X+Pvwzls75V84qou7cHEtnOBxIntnJU9CMg9xXxx8VPh5q/wAOfEb6bqqeZbSZa0vEXCXCeo9GHdex9QQSAcXRRRQAVseFvEeq+FtXi1PQryWzvYj8skZ6juCOjKe4NY9FAH3j8G/jbpvjKxtbTXTFp2uMAvJxDcN/sE9D/sn8M17HX5aWt7PbrsRz5edxQnjPr7H3r1jwH8fPGXhURQm7XV9OQAfZb7LMo9Fk+8Pxz9KAPvOkZQwIYAg9jXknw3+PfhHxk0drcTnRtUY4FteMArn/AGJOh+hwfavW1YMoKkEEZBHegDJ1Dw1o+oRul1p8Db+WKrtOfqK5rU/hfod6BsM8LBdowQ2BXeUUAeL6j8HpLSWSXSLhJlYYEcnykfj0qto/wq1p5A1/NbW655w25v04/WvcaKAPG9R+C5nLvFqiF2P8cZH8jXDa98KvEVkWjjtPtSnkSQHcD/UV9O0UAfLWn/DrxFP+6j064V+BmRdoH4muv8OfBG4IMmuX6RbiD5cA3H8SeP517tRQBxfh34aeGtCfzIbM3E3UPcNvwfYdK7JEWNAsahVHQKMAU6igAorz34ifF7wj4FWSLU9RW41FRxY2uJJc+jdl/wCBEV8nfFH4+eKPGvm2djIdG0Zsj7PbOfMkH+3J1P0GB9aAPefjT+0FpnhNZtK8JtBqmuYKvMDugtj7kffYf3Rx6ntXxjq+pXusalc6hqlzLdXtw5klmlbLOxqnRQAUUUUAFFFFABXTfD3wZq3jvxLb6NokBeV/mllP3IIweXY9gP1OAOTVDwr4d1TxVrtro+h2r3V9cNhUXoB3Zj2UdSTX2/4O8MeHvgH8N77UdRuFlu9gkvbro1xKAdsUYPbJwB7kn2ADxdrnh74B/C2Gx0hIjeBSllbStl7qY43SvjnA6k8DooxwK+FNW1G71bU7rUNRne4vLmRpZZXOSzE5Jrovib471X4heJ5dY1hlQY8u3t0+5BFnIQevXJPc/gByVABRRRQAUUUUAFFFFABVi3+4frVerFv9w/WgCF/vt9abTn++31ptABRRRQAUUUUAFFFFABRRRQB0PgTxdq3gjxHbazoU5iuIjh0P3Jk7o47qf04IwQDX29pWpeEPj78O5Le4RS2B59uSPPsZscMp/PDdCMg9xXwBXQ+BfF2r+CfEVvrOg3BhuYuHQ8pMh6o47qf8CMEA0AafxU+Hmr/DnxG+m6qnmW0hLWl4i4S4T1How4yvY+owTxdffXhPxX4K+O/hKXTr+1ikuVQPc6dP/rbdunmRt1IycB19cEDOK+XvjN8FNa+Hdw15b79T8Pux8u7jQ7oRnhZgPun/AGuh9ulAHk1FFFABRRRQApJOMnpXqHwz+NvizwL5dvFc/wBpaSp5srtiwUf7DdV/l7V5dRQB+i/wx+Knhz4hWKPpdx9n1ALmWwnIEqHvj+8PcfpXe1+WlnfXVlOk1pPJDMhyjoxBU+xr2XwH+0X4v0BoYdXuV1ezXhhdDMn/AH2OfzzQB9zUV846b+1d4dkm26loOp26f34XSXJ+h212Fn+0V8Obi3WR9WuLdiMmOW0k3L7HAI/I0AevUV5Hc/tEfDmGEyJq80xH8EdrJuP5gCuG1n9qzSEmki0XQbqZR9ye6lEYJ91XJx+NAH0rTJpY4ImlmdI40GWdzgAepNfDfiL9pPx5qTSJYXFlpkRYlfs0AZgPTL5rzrWfH3ijW8/2trd9eZzxNMzAewXoPyoA+0vGvx48JeHBcRWcz6tdxLkrbcRA+hkPH5Zr5z8fftEeK/EW+302RNJsW4aO1JDsPQydfyxXi088s7bppGY+9RUAPmkeaV5JGLO5LMSckk0yiigAooooAKKKKACtvwh4W1jxfrUOleH7KS7u5DyFHyxrn7zt0VR6muh+FXww174jaqsOlwmHTY5At1qEi/uoR1IH95sdFHqM4HNfYlnaeC/gB4AkldiqsRvlIDXN9NjhQP5DgKMn1JAK3gXwj4X+BHgS51PV7qL7WUBvr9l+aVu0UQ64z0XqTyfb5L+MnxQ1T4la959zuttJt2Is7ENkRj+83q57n8BTfjD8UNW+JWuC4vM2ul25ItLFWysY/vMf4nPc/gK8+oAKKKKACiiigAooooAKKKKACrFv9w/Wq9WLf7h+tAEL/fb602nP99vrTaACiiigAooooAKKKKACiiigAooooA0dA1rUfD+qwanot5NZX8BzHNE2CPUe4PcHg19kfBv486P43tY9B8Yrb2WsSRiEmXH2e+zwQAeFY/3Dwc8eg+JqKAPrX4wfs0xXTTar8PTHBL959KlbCNx/yyY9D/stxzwR0r5Y1rSdQ0TUptP1iznsr2E4khnQoy/ge3v3r274OftD6t4W+z6V4s83VtFBCrOWzcW4z1yfvjnoefQ9q+lb7S/AXxo8MxXLraarblcJcRNtuLY9dpI+ZCM8qfXpQB+d1Fe8/E39m7xH4cM954YZtd0xct5aDFzGoGeU6P3+7yfSvCZEaORkkVkdSVZWGCCOxFADKKKKACiiigAooooAKKKKACiiigAooooAKKKKACilALEAAkngAV618NfgN4u8aGG6ntjo2kvhvtV4hDOp7pH1bjoTgHI5oA8pt4JbmeOC2ieaaRgiRxqWZmPQADkmvpT4Q/s03d8YtU+IJaztc5TTIz+9k6/6xgfkHTgZJ/2e/tPg34d+Bvg9pD6rNJBFcQoRNq2oOA/PVV7LnGAqjJ6c5rxP4w/tJ3epiXSvAHmWVmcrJqUgxNJz/wAsx/APc8nP8PcA9k+IvxQ8I/CHRo9I063t5NQhjAt9Js8IEBBwXIGFHHPVjnODnNfFfj3xvrvjrWW1HxDeNO4JEMI4igUnO1F7D9TjkmudmlknmeWZ2klkYs7ucsxPJJPc1HQAUUUUAFFFFABRRRQAUUUUAFFFFABVi3+4frVerFv9w/WgCF/vt9abTn++31ptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWz4V8S6x4U1eLU/D9/NZXkZHzRnhh/dZejD2IIrGooA+t/ht+1FaXIhsvHtl9ll4X+0LNS0ZOcZePqvHJ2574A6V6X4g+G/wAOfirZHVoorW4kuAWGpaZMFkJ6ZJGQTwR8wPfvX5+1qaB4g1jw9dm50LU7zT5yMF7aVkJ4I5x16mgD2nx3+zL4q0eZpfC8kWu2ZPyruWGdR7qx2n8D+FeKa1oWraHctb6zpt7YTrgFLmFoyMjI6j0rpP8Aha/j7/ob9a/8Cm/xqO4+J/je6j8u68T6pPHnOyaYuufXB4oA42ipJpXnmkllYtJIxdmPcnkmo6ACiiigAooooAKKKKACiirmlald6VeLd6dO0FwoIDrjIB69aANnwt4F8UeKphH4f0K/vc4BkSIrGuQSN0hwoyBxkjNe2+DP2V9avfLm8Watb6bEeTBajzpccHBbhQeWHfGO9eRr8VfHiqFTxbrKqBgAXLAAegFH/C1/H3/Q361/4FN/jQB9n6D8Pfhz8KrA6nJBZ2rQqN2o6nKHkyCOQW4BJxwgHJ4FeefEH9qPSbBZLbwTYtqdwCQLu7Vo4B15C8O3b+71r5Q17XdV8QXpu9c1G71C5PHmXEpc9AOM9OAPyrMoA6Txr438ReNr8XfiXU5rx1+5Gfljj/3UHA/KuboooAKKKKACiiigAooooAKKKKACiiigAooooAKsW/3D9ar1Yt/uH60AQv8Afb602nP99vrTaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKsW/wBw/Wq9WLf7h+tAEL/fb602rLwrvPJ60nkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9FWPJX1NHkr6mgCvRVjyV9TR5K+poAr0VY8lfU0eSvqaAK9WLf7h+tHkr6mp4IV2Hk9aAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8656=[""].join("\n");
var outline_f8_29_8656=null;
var title_f8_29_8657="VLDL metabolism";
var content_f8_29_8657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endogenous pathway of lipid metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endogenous pathway begins with the synthesis in the liver of nascent VLDL particles, containing apolipoproteins (apo) B-100 and E. Cholesteryl esters and other apolipoproteins, some of which are derived from HDL catabolism, are added to form the mature VLDL particle. The lipolytic action of lipoprotein lipase (for which apo C-II is the primary ligand) cleaves VLDL into smaller VLDL remnants that are enriched in apo B-100 and E. The remnants are either cleared by the LDL and remnant receptors in the liver or hydrolyzed by hepatic triglyceride lipase to yield LDL particles containing apo B-100.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8657=[""].join("\n");
var outline_f8_29_8657=null;
var title_f8_29_8658="Patient information: Gallstones (The Basics)";
var content_f8_29_8658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15434\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/26/42401\">",
"         Patient information: Pancreatitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/21/7507\">",
"         Patient information: Gallstones (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gallstones (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gallstones-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H464403495\">",
"      <span class=\"h1\">",
"       What is the gallbladder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The gallbladder is a small, pear-shaped organ that is tucked under your liver (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ). It stores bile, a fluid that helps the body break down fat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403502\">",
"      <span class=\"h1\">",
"       What are gallstones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gallstones are small stones that form inside the gallbladder. They can be tiny specks or get as big as the whole gallbladder, which can be up to 6 inches long.",
"     </p>",
"     <p>",
"      Normally, the gallbladder fills with bile in between meals. Then, when you eat fatty foods, the gallbladder empties the bile into the intestine. Sometimes, though, gallstones clog the gallbladder and keep it from draining. Other times, gallstones just irritate the gallbladder. If the gallstones are pushed out of the gallbladder, they can keep the liver or pancreas from draining.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403509\">",
"      <span class=\"h1\">",
"       What are the symptoms of gallstones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, gallstones do not cause any symptoms. When they do cause symptoms, gallstones can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain &ndash; often on the right side just under the rib cage or in the middle top portion of the belly",
"       </li>",
"       <li>",
"        Pain in the back or right shoulder",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you know that you have gallstones but have no symptoms, you probably will not need treatment. But if you start having symptoms, you should get treated. The symptoms can come and go, but they often get worse over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403516\">",
"      <span class=\"h1\">",
"       Are gallstones serious?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. In rare cases they can lead to serious problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Jaundice, a condition that turns your skin and eyes yellow",
"       </li>",
"       <li>",
"        Infection",
"       </li>",
"       <li>",
"        Gallbladder tears, which can lead to death",
"       </li>",
"       <li>",
"        Inflammation of the pancreas (the pancreas is an organ that makes hormones and juices involved in food breakdown)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403523\">",
"      <span class=\"h1\">",
"       Is there a test for gallstones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, doctors can find out if you have gallstones by doing an imaging test, such as an ultrasound. An ultrasound is a painless test that uses sound waves to make an image of your gallbladder.",
"     </p>",
"     <p>",
"      Even if tests show that you have gallstones, that does not mean they are causing symptoms. Your doctor might need to do other tests to make sure your stones and your symptoms are related.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403530\">",
"      <span class=\"h1\">",
"       How are gallstones treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with gallstones generally have 3 treatment options. They can have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         No treatment",
"        </strong>",
"        &ndash; This option is best for people with no symptoms. If they start having symptoms, they can think about treatment then.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery to remove the gallbladder and the stones",
"        </strong>",
"        &ndash; Gallbladder surgery is routine in the United States. But it involves using anesthesia, so it has some risks. The surgery does not affect digestion very much. But about half the people who have surgery have mild symptoms afterward, including watery bowel movements, gas, or bloating. These symptoms usually get better. People who have their gallbladder removed do not need to worry about gallstones coming back.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatment to get rid of the stones but keep the gallbladder",
"        </strong>",
"        &ndash; People who choose this approach can take medicines to break up gallstones or be treated with a device that breaks up stones (or both). These treatments can work, but they take time &mdash; months to years. People with severe symptoms might not want to wait that long to feel better. Plus, the stones can come back after these treatments.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403537\">",
"      <span class=\"h1\">",
"       How do I know which treatment to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How large your stones are",
"       </li>",
"       <li>",
"        Whether you have symptoms, and how bad the symptoms are",
"       </li>",
"       <li>",
"        How you feel about the treatment options",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Ask your doctor or nurse how each treatment might affect you. Then work with him or her to find the treatment that makes the most sense for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403544\">",
"      <span class=\"h1\">",
"       Can I do anything to keep from getting (more) gallstones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can try to keep yourself at a healthy weight. People who are overweight are more likely to get gallstones.",
"     </p>",
"     <p>",
"      If you plan to lose weight quickly &mdash; even if you have never had gallstones &mdash; ask your doctor or nurse what you can do to keep from getting gallstones. Losing weight quickly &mdash; for example, through weight loss surgery &mdash; can lead to gallstones. But your doctor or nurse can give you medicines to keep that from happening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H464403551\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=see_link\">",
"       Patient information: Pancreatitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       Patient information: Gallstones (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/29/8658?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15434 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-1C172F50BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8658=[""].join("\n");
var outline_f8_29_8658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403495\">",
"      What is the gallbladder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403502\">",
"      What are gallstones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403509\">",
"      What are the symptoms of gallstones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403516\">",
"      Are gallstones serious?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403523\">",
"      Is there a test for gallstones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403530\">",
"      How are gallstones treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403537\">",
"      How do I know which treatment to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403544\">",
"      Can I do anything to keep from getting (more) gallstones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464403551\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=related_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8659="Metastasis small intestine US";
var content_f8_29_8659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastasis to the small intestine on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An echopoor region (met) is visible adjacent to the jejunum in a patient later confirmed to have metastatic meloma. The lesion was confirmed to be melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8659=[""].join("\n");
var outline_f8_29_8659=null;
var title_f8_29_8660="Epinastine: Patient drug information";
var content_f8_29_8660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epinastine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/60/16323?source=see_link\">",
"     see \"Epinastine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35314?source=see_link\">",
"     see \"Epinastine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elestat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to epinastine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses if your eyes are red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 10 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11259 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8660=[""].join("\n");
var outline_f8_29_8660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016649\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016648\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016653\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016654\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016656\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016651\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016652\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016657\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016658\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/60/16323?source=related_link\">",
"      Epinastine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35314?source=related_link\">",
"      Epinastine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8661="Interferon beta-1b: Patient drug information";
var content_f8_29_8661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Interferon beta-1b: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     see \"Interferon beta-1b: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betaseron&reg;;",
"     </li>",
"     <li>",
"      Extavia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaseron&reg;;",
"     </li>",
"     <li>",
"      Extavia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Beta interferons may cause or make diseases of the mind worse. Taking one's own life, ideas of killing yourself or murder, or low mood (depression) have happened with use. If you think you have any of these problems, call your doctor right away. Problems are most often fixed after you stop the drug. Very bad liver problems have been reported. Your doctor will watch you closely during the first 24 weeks of therapy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702310",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to interferon beta-1b or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to help with flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10767 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8661=[""].join("\n");
var outline_f8_29_8661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183545\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183546\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027654\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027656\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027655\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027660\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027661\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027663\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027658\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027659\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027664\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027665\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=related_link\">",
"      Interferon beta-1b: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8662="Periocular atopic dermatitis";
var content_f8_29_8662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques with fine scale are present on the periocular skin in this patient with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8662=[""].join("\n");
var outline_f8_29_8662=null;
var title_f8_29_8663="Cecal volvulus";
var content_f8_29_8663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cecal volvulus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Richard A Hodin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8663/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/29/8663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cecal volvulus is the rotation or torsion of a flexible cecum and ascending colon, frequently progressing to bowel obstruction, ischemia, necrosis, and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Volvuli can occur at other sites in the alimentary tract, including the sigmoid colon, stomach, gallbladder, splenic flexure, and small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cecal volvulus ranges from 2.8 to 7.1 per million people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Cecal volvulus accounts for approximately 1 to 3 percent of all large intestinal obstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Depending upon the series and age of the patients, cecal volvulus represents 10 to 52 percent of all cases of colonic volvuli [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/4,11-15\">",
"     4,11-15",
"    </a>",
"    ]. For example, a retrospective review of 137 patients with a colonic volvulus identified the following segments involved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cecum &ndash; 52 percent",
"     </li>",
"     <li>",
"      Sigmoid &ndash; 43 percent",
"     </li>",
"     <li>",
"      Transverse colon &ndash; 3 percent",
"     </li>",
"     <li>",
"      Splenic flexure &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a cecal volvulus are young, with a mean age varying from 33 years in India to 53 years in Western countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In contrast, sigmoid volvulus usually occurs in elderly subjects with chronic constipation or distal colon obstruction. The patients are often institutionalized and debilitated with neurologic and psychiatric conditions, such as Parkinson disease and schizophrenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26453?source=see_link\">",
"     \"Sigmoid volvulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330622\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of cecal volvuli [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 &ndash; Cecal volvulus develops from clockwise axial torsion or twisting of the cecum around its mesentery, including the ascending colon and terminal ileum.",
"     </li>",
"     <li>",
"      Type II &ndash; Loop volvulus develops from a counterclockwise axial torsion of the cecum around its mesentery, including the ascending colon and terminal ileum.",
"     </li>",
"     <li>",
"      Type III &ndash; Cecal bascule involves the upward folding of the cecum rather than axial twisting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Type I and type II axial torsion cecal volvuli are the most common and account for approximately 80 percent of cecal volvuli, while cecal bascule accounts for approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/4\">",
"     4",
"    </a>",
"    ]. All three types require a mobile cecum and ascending colon, whether congenital or acquired. A cecal volvulus typically occurs in patients who have inherently increased cecal mobility, hypothesized to result from a congenital failure of the fusion of the ascending colon mesentery and the posterior parietal peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. Based upon autopsy studies, approximately 10 to 25 percent of the population has a cecum and ascending colon with sufficient mobility to develop a volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,19\">",
"     6,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired anatomic abnormalities, such as surgical adhesions, can also contribute to the development of a cecal volvulus. Clinical settings that have been associated with cecal volvulus include pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/20\">",
"     20",
"    </a>",
"    ], colonic atony [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"     6",
"    </a>",
"    ], colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/21\">",
"     21",
"    </a>",
"    ], Hirschsprung's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/22\">",
"     22",
"    </a>",
"    ], and mobile cecum syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330537\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330561\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation is highly variable, ranging from insidious, intermittent episodes of abdominal pain to an acute abdominal catastrophe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/1,6,9,12,24-26\">",
"     1,6,9,12,24-26",
"    </a>",
"    ]. Most patients present with a gradual onset of steady abdominal pain superimposed with cramping pain associated with peristalsis, as well as nausea, vomiting, and obstipation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. The duration of symptoms also varies from hours to days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The elements of a comprehensive history for a patient with acute abdominal pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88017398\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is also variable, with fever and hypotension present in the patient with vascular compromise, with or without perforation. Patients with a partial or complete bowel obstruction without ischemic bowel may have a normal temperature, blood pressure, and heart rate.",
"   </p>",
"   <p>",
"    The abdomen is generally diffusely distended and tympanitic, but in some clinical settings, the abdomen can be asymmetrically distended with tympany only in the mid-abdomen or the right or left upper quadrant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"     6",
"    </a>",
"    ]. Rebound tenderness can be elicited in the clinical setting of peritonitis or ischemic bowel. The approach to performing a physical examination in the acute clinical setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330577\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CT scan",
"      </strong>",
"      &ndash; Computerized tomography scan (CT scan) demonstrates the &ldquo;whirl sign&rdquo;, twisting of the mesentery around the ileocolic vessels, which is pathognomonic of axial cecal volvulus [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/4,6,7,11,28,29\">",
"       4,6,7,11,28,29",
"      </a>",
"      ]. CT scan can also demonstrate a massively dilated cecum with associated small bowel dilation and signs of colonic or small bowel ischemia such as mural thickening and mesenteric edema (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87765 \" href=\"UTD.htm?16/29/16855\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87766 \" href=\"UTD.htm?12/49/13077\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/7\">",
"       7",
"      </a>",
"      ]. For patients with cecal bascule, CT scan can show the cecum folding upward, resulting in obstruction, without the axial twist of the mesentery (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87137 \" href=\"UTD.htm?19/35/20025\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Contrast studies",
"      </strong>",
"      &ndash; A single-contrast",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      or hypaque enema demonstrates a tapered or &ldquo;bird&rsquo;s beak&rdquo; narrowing in the right colon, confirming a cecal volvulus (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87764 \" href=\"UTD.htm?39/55/40817\">",
"       image 4",
"      </a>",
"      ). In cecal bascule, the termination of contrast is rounded as a result of the transversely folded cecum [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/7,11,30\">",
"       7,11,30",
"      </a>",
"      ]. In a retrospective review of 568 patients with cecal volvulus, barium enema was diagnostic in 88 percent, and abdominal plain film suggested the diagnosis in 46 percent of patients, but was diagnostic in only 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Upright abdominal plain films",
"      </strong>",
"      &ndash; A plain, upright abdominal film reveals the classic &ldquo;comma&rdquo; or &ldquo;coffee bean&rdquo; shaped cecum with an air-fluid level in approximately 25 percent of patients (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71577 \" href=\"UTD.htm?6/28/6607\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80286 \" href=\"UTD.htm?9/46/9954\">",
"       image 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,29\">",
"       6,29",
"      </a>",
"      ]. The dilated cecum is typically displaced medially and superiorly, although it can be displaced anywhere in the abdomen [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition, the proximal small bowel is distended with air fluid levels while the distal colon is decompressed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]. Cecal bascule can demonstrate similar findings with a more central position of the dilated cecum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87136 \" href=\"UTD.htm?2/17/2321\">",
"       image 7",
"      </a>",
"      ). Free air can be identified under the diaphragm in the clinical setting of a bowel perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330585\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are not diagnostic of cecal volvulus. However, leukocytosis may indicate a perforation or gangrenous, necrotic bowel. Vomiting associated with a bowel obstruction can result in hypokalemia and other electrolyte imbalances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Surgical abdomen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9581969\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scan confirms the diagnosis of cecal volvulus in approximately 90 percent of patients, the remainder are diagnosed at the time of an exploratory operative procedure (ie, laparotomy, laparoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/4,6,25,29\">",
"     4,6,25,29",
"    </a>",
"    ]. A history and physical examination alone cannot confirm the diagnosis. Plain abdominal radiographs can diagnose a large intestine obstruction, but are insufficient to confirm the diagnosis of cecal volvulus in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330637\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intestinal obstruction should be suspected when a patient presents with symptoms that include abdominal pain, nausea, and vomiting, and a physical examination that reveals a distended and tympanic abdomen. However, the specific diagnosis of cecal volvulus is rarely made by the history and physical examination alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/26\">",
"     26",
"    </a>",
"    ]. Systemic findings, such as fever or hypotension, and leukocytosis may indicate necrotic bowel or perforation.",
"   </p>",
"   <p>",
"    The diagnostic evaluation includes an upright abdominal plain film to identify an obstruction or pneumoperitoneum. No further diagnostic imaging is necessary for patients with a pneumoperitoneum; they should be prepared for an immediate operative procedure. In the clinical setting of an obstructive process, a CT scan can be obtained to delineate the location of the obstruction as well as the presence of ischemic bowel. A CT scan demonstrating a &ldquo;whirl sign&rdquo; confirms the diagnosis of cecal volvulus in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/4,7,11,28,29\">",
"     4,7,11,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A contrast enema (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    or Hypaque) can be performed if the CT scan is nondiagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Contrast studies are contraindicated in the clinical setting of necrotic bowel or pneumoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/7,11,16\">",
"     7,11,16",
"    </a>",
"    ]. In addition, the contrast should be gently inserted to avoid colonic perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12330577\">",
"     'Imaging studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An exploratory operative procedure (laparoscopy or laparotomy) is a diagnostic tool that should be used when imaging studies fail to establish a diagnosis in a patient with worsening obstructive symptoms or an abdominal catastrophe.",
"   </p>",
"   <p>",
"    The diagnostic approach to a patient with acute abdominal pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12330593\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sigmoid volvulus &ndash; Sigmoid volvulus is the axial torsion of the sigmoid colon, which often leads to a bowel obstruction and ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"       6",
"      </a>",
"      ]. In contrast to patients with a cecal volvulus, sigmoid volvulus usually occurs in elderly subjects who are often institutionalized and debilitated with neurologic and psychiatric conditions such as Parkinson disease and schizophrenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26453?source=see_link\">",
"       \"Sigmoid volvulus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mobile cecum syndrome &ndash; Mobile cecum syndrome occurs when the cecum and ascending colon lack a posterior peritoneal attachment [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients typically present with chronic right lower quadrant abdominal pain and abdominal distention that is relieved with passage of flatus or stool.",
"     </li>",
"     <li>",
"      Transverse colon volvulus and splenic flexure volvulus &ndash; The transverse colon and splenic flexure can each become torsed and form a rare large intestinal volvulus; patients present with abdominal pain and distention, and the volvulus can result in bowel obstruction, ischemia, and perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"       6",
"      </a>",
"      ]. These patients typically have a mobile transverse colon or splenic flexure as a result of a congenital or acquired loss of colonic attachments. The evaluation is similar to that described for a cecal volvulus. (See",
"      <a class=\"local\" href=\"#H12330637\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ileosigmoid knotting &ndash; Ileosigmoid knotting is a rare condition in which the distal ileum wraps itself around the base of the sigmoid colon, resulting in a closed loop colonic obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"       6",
"      </a>",
"      ]. It is more frequently diagnosed in patients residing in Asia, Africa, and the Middle East than in the US.",
"     </li>",
"     <li>",
"      Gastric volvulus &ndash; Gastric volvulus is rare and characterized by rotation of the stomach along its long or short axis, leading to variable degrees of gastric outlet obstruction, which may present acutely or chronically. Presentation typically includes abdominal or chest pain, nausea, and vomiting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7289?source=see_link\">",
"       \"Gastric volvulus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Distal small bowel obstruction &ndash; A patient with a distal small bowel obstruction can present with abdominal pain, nausea, vomiting, and abdominal distention. Plain abdominal films reveal distended loops of small bowel with a paucity of air in the colon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemic bowel &ndash; Mesenteric ischemia, either acute or chronic, is caused by a reduction in intestinal blood flow and can result in bowel infarction and sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"       \"Acute mesenteric ischemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"       \"Chronic mesenteric ischemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cecal diverticulitis &ndash; Cecal diverticulitis usually occurs in young adults and presents with signs and symptoms of right-sided abdominal pain, nausea, and vomiting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"       \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13450?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of acute diverticulitis\", section on 'Right-sided (cecal) diverticulitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appendicitis &ndash; Acute appendicitis typically begins with mid-abdominal pain that radiates to the right lower quadrant, and can be associated with nausea and vomiting. The symptoms of appendicitis vary depending upon the location of the tip of the appendix (",
"      <a class=\"graphic graphic_figure graphicRef64911 \" href=\"UTD.htm?5/5/5200\">",
"       figure 1",
"      </a>",
"      ). Fever and leukocytosis are associated with a perforation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"       \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right lower quadrant abdominal pain differential &ndash; Additional intestinal, gynecologic, obstetrical, and urologic clinical settings that can be included in the differential diagnosis of right lower quadrant abdominal pain are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link&amp;anchor=H5345977#H5345977\">",
"       \"Acute appendicitis in adults: Clinical manifestations and diagnosis\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83008274\">",
"    <span class=\"h2\">",
"     Operative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management for patients with a cecal volvulus is operative. The suggested procedure is a right colectomy or an ileocecal resection with an ileocolic anastomosis, based upon retrospective and consecutive patient series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,26,31\">",
"     6,26,31",
"    </a>",
"    ], although cecopexy or colopexy, and cecostomy (alone or in conjunction with a resection), are described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/9-11,16,31-33\">",
"     9-11,16,31-33",
"    </a>",
"    ]. However, no randomized trials have been performed to determine the optimal surgical procedure. Laparotomy or a laparoscopic approach can be used, although the preferred approach is laparotomy in the clinical setting of greatly distended bowel.",
"   </p>",
"   <p>",
"    Operative management is based upon intraoperative findings and patient stability:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volvulus",
"      <strong>",
"       without",
"      </strong>",
"      ischemia, necrosis, or perforation &ndash; If the colon is viable, detorsion is performed in conjunction with a bowel resection, such as a right colectomy or ileocolic resection. A right colectomy removes the cecum and entire ascending colon, while an ileocolic resection leaves a remnant of ascending colon. If the entire ascending colon is mobile, then a right colectomy is preferred. If only the cecum is unattached to the posterior parietal peritoneum, the more limited ileocolic resection can be performed. Recurrence rate of cecal volvulus after right colectomy is essentially zero; however, the mortality rate after resection ranges from &lt;5 to 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,14,16,25\">",
"       6,14,16,25",
"      </a>",
"      ]. Intra-operative detorsion alone is associated with a failure rate ranging from 13 to 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,34\">",
"       6,34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Colopexy of the right colon remnant to the posterior peritoneal wall has been performed to prevent volvulus recurrence following an ileocolic resection, with no evidence of recurrence in one series of 10 consecutive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/31\">",
"       31",
"      </a>",
"      ]. If an ileocolic resection is performed, a colopexy should be considered to reduce the risk of recurrence.",
"      <br/>",
"      <br/>",
"      Cecopexy can be performed alone, in conjunction with a cecostomy tube placement, or with appendectomy to encourage formation of adhesions to reduce the mobility of the cecum [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/33,35,36\">",
"       33,35,36",
"      </a>",
"      ]. The recurrence rates vary from 0 to 28 percent and the mortality rates range from 0 to 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cecostomy tube placement can decompress the right colon, but is typically reserved for debilitated or unstable patients. Ongoing intraperitoneal fecal contamination, surgical site infections, and colocutaneous fistula are complications of this procedure. The recurrence rate is low (2 to 14 percent) due to the adhesions created between the cecum and the abdominal wall, but the mortality rates are high, ranging from 0 to 33 percent, most likely reflecting the range of patient comorbidities or clinical instability [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,14,16,27,32\">",
"       6,14,16,27,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volvulus",
"      <strong>",
"       with",
"      </strong>",
"      ischemia, necrosis, or perforation &ndash; An ileocolic resection or a right colectomy, without a detorsion maneuver, is performed when ischemia, necrosis, or perforation is present [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,11,31\">",
"       6,11,31",
"      </a>",
"      ]. The type of resection depends upon the extent of ischemic or gangrenous bowel, as well as the mobility of the ascending colon. It is unlikely that sufficient reperfusion will occur following detorsion; in addition, surgical detorsion is not suggested for gangrenous or necrotic bowel as reperfusion may promote bacteremia and sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If the patient is clinically unstable, an ileostomy rather than a primary ileocolic anastomosis can be performed. A cecostomy as the primary operative procedure should not be performed for any but the most clinically unstable patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/16\">",
"       16",
"      </a>",
"      ]. The mortality rate for patients with gangrenous cecal volvulus ranges from 17 to 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83008393\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest nonoperative management (eg, colonoscopy, reduction",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema) for detorsion of a cecal volvulus because of the 20 to 25 percent risk of concurrent cecal necrosis, failure rates with nonoperative procedures approaching 95 percent, and risk of colon perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8663/abstract/6,9,13,32,37,38\">",
"     6,9,13,32,37,38",
"    </a>",
"    ]. In addition, colonoscopic detorsion of cecal volvulus, unlike a sigmoid volvulus, is technically challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with cecal volvulus have full axial rotation, causing twisting of the mesentery and blood vessels (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71577 \" href=\"UTD.htm?6/28/6607\">",
"       image 5",
"      </a>",
"      ). In approximately 20 percent of cases, the cecum and ascending colon fold in an anterior cephalad direction, known as a cecal bascule. (See",
"      <a class=\"local\" href=\"#H12330622\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation is highly variable, ranging from insidious, intermittent episodes of abdominal pain to an acute abdominal catastrophe. The physical examination typically reveals a distended and tympanic abdomen. (See",
"      <a class=\"local\" href=\"#H12330537\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computerized tomography scan (CT scan) demonstrates the &ldquo;whirl sign&rdquo;, twisting of the mesentery around the ileocolic vessels, which is pathognomonic of an axial cecal volvulus. (See",
"      <a class=\"local\" href=\"#H12330577\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CT scan confirms the diagnosis of a cecal volvulus in approximately 90 percent of patients; the remainder are diagnosed intra-operatively. Plain abdominal films are insufficient to correctly diagnose cecal volvulus in most patients. (See",
"      <a class=\"local\" href=\"#H9581969\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a cecal volvulus and a completely mobile cecum and ascending colon (not attached to the posterior parietal peritoneum), we suggest a right colectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If only the cecum is mobile, a more limited ileocolic resection can be performed. There is essentially no risk of a recurrent cecal volvulus following a right colectomy. If an ileocolic resection is performed, a colopexy should be considered. (See",
"      <a class=\"local\" href=\"#H83008274\">",
"       'Operative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing nonoperative procedures, such as colonoscopy or reduction",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema, for detorsion of a cecal volvulus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H83008393\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/1\">",
"      Katoh T, Shigemori T, Fukaya R, Suzuki H. Cecal volvulus: report of a case and review of Japanese literature. World J Gastroenterol 2009; 15:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/2\">",
"      Pousada L. Cecal bascule: an overlooked diagnosis in the elderly. J Am Geriatr Soc 1992; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/3\">",
"      Consorti ET, Liu TH. Diagnosis and treatment of caecal volvulus. Postgrad Med J 2005; 81:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/4\">",
"      Delabrousse E, Sarli&egrave;ve P, Sailley N, et al. Cecal volvulus: CT findings and correlation with pathophysiology. Emerg Radiol 2007; 14:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/5\">",
"      Perret RS, Kunberger LE. Case 4: Cecal volvulus. AJR Am J Roentgenol 1998; 171:855, 859, 860.",
"     </a>",
"    </li>",
"    <li>",
"     Yee LF. Colonic volvulus. American Society of Colon &amp; Rectal Surgeons (ASCRS). file://www.fascrs.org/physicians/education/core_subjects/2006/colonic_volvulus/ (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/7\">",
"      Peterson CM, Anderson JS, Hara AK, et al. Volvulus of the gastrointestinal tract: appearances at multimodality imaging. Radiographics 2009; 29:1281.",
"     </a>",
"    </li>",
"    <li>",
"     Rakinic J. Colonic volvulus. In: The ASCRS textbook of colon and rectal surgery, 2nd, Beck DE, Roberts PL, Saclarides TJ, et al.  (Eds), Springer, New York 2011. p.395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/9\">",
"      Lee SY, Bhaduri M. Cecal volvulus. CMAJ 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/10\">",
"      Baldarelli M, De Sanctis A, Sarnari J, et al. Laparoscopic cecopexy for cecal volvulus after laparoscopy. Case report and a review of the literature. Minerva Chir 2007; 62:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/11\">",
"      Abita T, Lachachi F, Durand-Fontanier S, et al. [Cecal volvulus]. J Chir (Paris) 2005; 142:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/12\">",
"      Ballantyne GH, Brandner MD, Beart RW Jr, Ilstrup DM. Volvulus of the colon. Incidence and mortality. Ann Surg 1985; 202:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/13\">",
"      Friedman JD, Odland MD, Bubrick MP. Experience with colonic volvulus. Dis Colon Rectum 1989; 32:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/14\">",
"      Hiltunen KM, Syrj&auml; H, Matikainen M. Colonic volvulus. Diagnosis and results of treatment in 82 patients. Eur J Surg 1992; 158:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/15\">",
"      P&aring;hlman L, Enblad P, Rudberg C, Krog M. Volvulus of the colon. A review of 93 cases and current aspects of treatment. Acta Chir Scand 1989; 155:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/16\">",
"      Rabinovici R, Simansky DA, Kaplan O, et al. Cecal volvulus. Dis Colon Rectum 1990; 33:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/17\">",
"      Gupta S, Gupta SK. Acute caecal volvulus: report of 22 cases and review of literature. Ital J Gastroenterol 1993; 25:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/18\">",
"      Husain K, Fitzgerald P, Lau G. Cecal volvulus in the Cornelia de Lange syndrome. J Pediatr Surg 1994; 29:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/19\">",
"      DONHAUSER JL, ATWELL S. Volvulus of the cecum with a review of 100 cases in the literature and a report of six new cases. Arch Surg 1949; 58:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/20\">",
"      John H, Gyr T, Giudici G, et al. Cecal volvulus in pregnancy. Case report and review of literature. Arch Gynecol Obstet 1996; 258:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/21\">",
"      Radin DR, Halls JM. Cecal volvulus: a complication of colonoscopy. Gastrointest Radiol 1986; 11:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/22\">",
"      Sariolu A, Tanyel FC, B&uuml;y&uuml;kpamuk&ccedil;u N, Hi&ccedil;s&ouml;nmez A. Colonic volvulus: a rare presentation of Hirschsprung's disease. J Pediatr Surg 1997; 32:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/23\">",
"      Rogers RL, Harford FJ. Mobile cecum syndrome. Dis Colon Rectum 1984; 27:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/24\">",
"      Habre J, Sautot-Vial N, Marcotte C, Benchimol D. Caecal volvulus. Am J Surg 2008; 196:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/25\">",
"      Swenson BR, Kwaan MR, Burkart NE, et al. Colonic volvulus: presentation and management in metropolitan Minnesota, United States. Dis Colon Rectum 2012; 55:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/26\">",
"      Hashimoto Y, Shigemoto S, Nakashima A, et al. Successful preoperative diagnosis of a rare bowel obstruction: cecal volvulus. J Gastrointest Surg 2008; 12:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/27\">",
"      Anderson JR, Welch GH. Acute volvulus of the right colon: an analysis of 69 patients. World J Surg 1986; 10:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/28\">",
"      Moore CJ, Corl FM, Fishman EK. CT of cecal volvulus: unraveling the image. AJR Am J Roentgenol 2001; 177:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/29\">",
"      Rosenblat JM, Rozenblit AM, Wolf EL, et al. Findings of cecal volvulus at CT. Radiology 2010; 256:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/30\">",
"      Frank AJ, Goffner LB, Fruauff AA, Losada RA. Cecal volvulus: the CT whirl sign. Abdom Imaging 1993; 18:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/31\">",
"      Majeski J. Operative therapy for cecal volvulus combining resection with colopexy. Am J Surg 2005; 189:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/32\">",
"      Madiba TE, Thomson SR. The management of cecal volvulus. Dis Colon Rectum 2002; 45:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/33\">",
"      Jones RG, Wayne EJ, Kehdy FJ. Laparoscopic detorsion and cecopexy for treatment of cecal volvulus. Am Surg 2012; 78:E251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/34\">",
"      Tejler G, Jiborn H. Volvulus of the cecum. Report of 26 cases and review of the literature. Dis Colon Rectum 1988; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     Glasgow SC. Colonic volvulus. American Society of Colon &amp; Rectal Surgeons (ASCRS). www.fascrs.org/physicians/education/core_subjects/2012/colonic_volvulus/ (Accessed on October 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/36\">",
"      Shoop SA, Sackier JM. Laparoscopic cecopexy for cecal volvulus. Case report and a review of the literature. Surg Endosc 1993; 7:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/37\">",
"      Mellor MF, Drake DG. Colonic volvulus in children: value of barium enema for diagnosis and treatment in 14 children. AJR Am J Roentgenol 1994; 162:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8663/abstract/38\">",
"      Schwab FJ, Glick SN, Teplick SK. Reduction of cecal volvulus by multiple barium enemas. Gastrointest Radiol 1985; 10:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1374 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.231-4F3FA9F29D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8663=[""].join("\n");
var outline_f8_29_8663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12330622\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12330537\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12330561\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88017398\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12330577\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12330585\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9581969\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12330637\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12330593\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83008274\">",
"      Operative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83008393\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1374|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/29/16855\" title=\"diagnostic image 1\">",
"      Scout and coronal computerized tomography cecal volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/49/13077\" title=\"diagnostic image 2\">",
"      Computerized tomography cecal volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/35/20025\" title=\"diagnostic image 3\">",
"      Cecal bascule - CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/55/40817\" title=\"diagnostic image 4\">",
"      Barium enema cecal volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/28/6607\" title=\"diagnostic image 5\">",
"      Cecal volvulus KUB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/46/9954\" title=\"diagnostic image 6\">",
"      Cecal bascule barium enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/17/2321\" title=\"diagnostic image 7\">",
"      Cecal bascule - Abdominal films",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1374|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/5/5200\" title=\"figure 1\">",
"      Appendiceal anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7289?source=related_link\">",
"      Gastric volvulus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26453?source=related_link\">",
"      Sigmoid volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13450?source=related_link\">",
"      Treatment of acute diverticulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8664="Paclitaxel (nanoparticle albumin bound): Drug information";
var content_f8_29_8664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paclitaxel (nanoparticle albumin bound): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/24/22917?source=see_link\">",
"    see \"Paclitaxel (nanoparticle albumin bound): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abraxane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11571444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abraxane&reg; for Injectable Suspension",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Taxane Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When administered as part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence of administration. Premedication is not generally necessary prior to paclitaxel (protein bound), but may be needed in patients with prior mild-to-moderate hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic:",
"     </b>",
"     I.V.: 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC), locally advanced or metastatic:",
"     </b>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 8, and 15 of each 21-day cycle (in combination with carboplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer (unlabeled dosing):",
"     </b>",
"     I.V.: 100-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 8, and 15 of a 28-day cycle (Gradishar, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ovarian, fallopian tube, or primary peritoneal cancer (recurrent; unlabeled use):",
"     </b>",
"     I.V.: 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 21-day cycle for 6-8 cycles (Teneriello, 2009)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity (Coleman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatic cancer, metastatic (unlabeled use):",
"     </b>",
"     I.V.: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 8, and 15 of a 28-day cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (Von Hoff, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F205676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F205677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer (every 3 week regimen):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (AST &lt;10 times ULN and bilirubin &le;1.25 times ULN): No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (AST &lt;10 times ULN and bilirubin 1.26-2 times ULN): Reduce dose to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST &lt;10 times ULN and bilirubin 2.01-5 times ULN: Reduce dose to 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may increase up to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles (based on individual tolerance)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST &gt;10 times ULN or bilirubin &gt;5 times ULN: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC) regimen:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (AST &lt;10 times ULN and bilirubin &le;1.25 times ULN): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (AST &lt;10 times ULN and bilirubin 1.26-2 times ULN): Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST &lt;10 times ULN and bilirubin 2.01-5 times ULN: Reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may increase up to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles (based on individual tolerance)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST &gt;10 times ULN or bilirubin &gt;5 times ULN: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F205695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Breast cancer (every 3 week regimen):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe neutropenia",
"     </i>",
"     (&lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) &ge;1 week: Reduce dose to 220 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for subsequent courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrent severe neutropenia: Reduce dose to 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for subsequent courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sensory neuropathy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 1 or 2: Dosage adjustment generally not required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 3: Hold treatment until resolved to grade 1 or 2, then resume with reduced dose for all subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe sensory neuropathy: Reduce dose to 220 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for subsequent courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Recurrent severe sensory neuropathy: Reduce dose to 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for subsequent courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Neutropenia:",
"     </i>",
"     ANC &lt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold therapy until ANC is &ge;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 1 or &ge;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     on days 8 or 15. Reduce dose upon therapy reinitiation if:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neutropenic fever (ANC &lt; 500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever &gt;38&deg;C)",
"     <b>",
"      or",
"     </b>",
"     delay of next cycle by &gt;7 days due to ANC &lt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First occurrence: Permanently reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second occurrence: Permanently reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Third occurrence: Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Thrombocytopenia:",
"     </i>",
"     Platelet count &lt;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold therapy until platelet count is &ge;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 1 or &ge;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     on days 8 or 15. Reduce dose upon therapy reinitiation if:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First occurrence: Permanently reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second occurrence: Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sensory neuropathy:",
"     </i>",
"     Withhold therapy for grade 3-4 peripheral neuropathy. Resume therapy at reduced doses when neuropathy resolves completely or improves to grade 1:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First occurrence: Permanently reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second occurrence: Permanently reduce dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Third occurrence: Discontinue therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abraxane&reg;: 100 mg [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer over 30 minutes (limiting the infusion rate to 30 minutes reduces the risk for infusion-related reaction); do not use an in-line filter. Monitor infusion site; avoid extravasation. When given on a weekly (unlabeled) schedule, infusions were administered over ~30 minutes (Gradishar, 2009; Rizvi, 2008). When administered as part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence of administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3137116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS. Formulation contains albumin; do not mix with other drugs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory (metastatic) or relapsed (within 6 months of adjuvant therapy) breast cancer; first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) (in combination with carboplatin) in patients ineligible for curative surgery or radiation therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7992223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancers; metastatic pancreatic cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PACLitaxel may be confused with DOCEtaxel",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PACLitaxel (protein bound) may be confused with PACLitaxel (conventional)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Abraxane&reg; may be confused with Paxil&reg;, Taxol&reg;, Taxotere&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse reactions and incidences reported are associated with monotherapy unless otherwise stated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: ECG abnormal (60%; 35% in patients with a normal baseline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (25% combination therapy for NSCLC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (56% [combination therapy for NSCLC] to 90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (27% to 30%; grades 3/4: 3%), diarrhea (15% to 27%; grades 3/4: &lt;1%), vomiting (12% to 18%; grades 3/4: 4%), appetite decreased (17% combination therapy for NSCLC), constipation (16% combination therapy for NSCLC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (80%; grades 3/4: 34%; combination therapy for NSCLC: 85%; grades 3/4: 47%), anemia (33%; grades 3/4: 1%; combination therapy for NSCLC: 98%; grades 3/4: 28%), thrombocytopenia (2%; grades 3/4: &lt;1%; combination therapy for NSCLC: 68%; grades 3/4: 18%), myelosuppression (dose-related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (39%), alkaline phosphatase increased (36%), GGT increased (grades 3/4: 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Sensory neuropathy (71%; grades 3/4: 10%; dose dependent; cumulative), weakness (47%; severe 8%; combination therapy for NSCLC: 16%), myalgia/arthralgia (44%; combination therapy for NSCLC: 10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision disturbance (13%; severe [keratitis, blurred vision]: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (11%; severe 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (24%; primarily included oral candidiasis, respiratory tract infection, and pneumonia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema /fluid retention (10%),  peripheral edema (10% combination therapy for NSCLC), hypotension (5%), cardiovascular events (grades 3/4: 3%; included chest pain, cardiac arrest, supraventricular tachycardia, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (10% combination therapy NSCLC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Mucositis (7%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (2%), neutropenic fever (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (grade 3: 10%; combination therapy for NSCLC: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (7%), epistaxis (7% combination therapy for NSCLC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction (4%, includes anaphylactic reactions, chest pain, dyspnea, flushing, hypotension; severe: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmia, autonomic neuropathy, bradycardia, cardiac ischemia, cerebrovascular attack, congestive heart failure, cranial nerve palsies, cystoid macular edema (transient), dehydration, embolism, hand-foot syndrome (in patients previously exposed to capecitabine), injection site reaction (mild), interstitial pneumonia, intestinal obstruction, intestinal perforation, ischemic colitis, left ventricular dysfunction, maculopapular rash, MI, motor neuropathy, optic nerve damage (rare), pancreatitis, pancytopenia, paralytic ileus, photosensitivity reaction, pneumonitis, pneumothorax, pulmonary embolism, radiation pneumonitis with concurrent radiation therapy, radiation recall, Stevens-Johnson syndrome, stroke, thrombosis, toxic epidermal necrolysis, transient ischemic attack, ventricular dysfunction, vocal cord paresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse reactions reported with paclitaxel, which may occur with paclitaxel (protein bound): Cellulitis, conjunctivitis, extravasation recall, hepatic encephalopathy, hepatic necrosis, induration, lacrimation increased, lung fibrosis, neutropenic enterocolitis (typhlitis), optic nerve damage (persistent), phlebitis, pulmonary embolism, skin exfoliation, skin fibrosis, skin necrosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with a baseline neutrophil count of &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; severe hypersensitivity reaction to paclitaxel (protein bound)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression, primarily neutropenia, may occur; monitor peripheral blood counts frequently. Baseline neutrophils should be &ge;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      for administration",
"     </b>",
"     on day 1 of each cycle; platelets should recover to  &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to day 1 of the next treatment cycle. Hematologic toxicity is dose-dependent, dose-limiting, and reversible. For severe neutropenia, dose reductions may be recommended for subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Severe hypersensitivity reactions (including anaphylaxis) have been reported; do not rechallenge after severe hypersensitivity reaction. Premedication is not generally necessary prior to paclitaxel (protein bound), but may be needed in patients with prior mild-to-moderate hypersensitivity reactions. Use has not been studied in patients with a prior hypersensitivity reaction to conventional paclitaxel or albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Dose-related sensory neuropathy is common; severe sensory neuropathy may occur. If &ge; grade 3 sensory neuropathy occurs, withhold therapy until resolution to grade 1 or 2 (breast cancer) or &le; grade 1 (NSCLC). Upon recovery, subsequent cycles should be dose reduced. Prior therapy with neurotoxic agents may influence the frequency and severity of neurologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely; the risk of toxicities is increased. Reduced initial dosages are recommended for moderate and severe hepatic impairment; withhold treatment in patients with AST &gt;10 times ULN or bilirubin &gt;5 times ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Certain adverse events (myelosuppression, peripheral neuropathy, arthralgia) occurred more frequently in older adults &ge;65 years of age compared to younger adults in NSCLC trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product contains albumin, which confers a remote risk of viral disease transmission and a theoretical risk of transmission of Creutzfeldt-Jakob disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Do not interchange:",
"     <b>",
"      [U.S. Boxed Warning]: Paclitaxel (protein-bound) is not interchangeable with other forms of paclitaxel, including Cremophor&reg;-based or unbound paclitaxel.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Taxane Derivatives may enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: Taxane Derivatives may decrease the metabolism of DOXOrubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: PACLitaxel (Protein Bound) may enhance the neurotoxic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F205669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Paclitaxel (protein bound) serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease paclitaxel (protein bound) serum concentrations; avoid concurrent use. Avoid echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. An",
"     <i>",
"      ex vivo",
"     </i>",
"     human placenta perfusion model illustrated that paclitaxel (non-protein bound preparation) crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower paclitaxel placental transfer (Berveiller, 2012).  Women of childbearing potential should be advised to avoid becoming pregnant during therapy; may cause fetal harm if administered during pregnancy. Additionally, testicular atrophy/degeneration was observed in animal studies; males should be advised to not father a child during therapy. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877- 635-4499).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paclitaxel (non-protein bound) is excreted in breast milk (case report). The mother (3 months postpartum) was treated with paclitaxel 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (56.1 mg) and carboplatin once weekly for papillary thyroid cancer. Milk samples were obtained 4-316 hours after the infusion given at the sixth and final week of therapy. The average paclitaxel milk concentration over the testing interval was 0.78 mg/L. Although maternal serum concentrations were not noted in the report, the relative infant dose to a nursing infant was calculated to be ~17% of the maternal dose. Paclitaxel continued to be detected in breast milk when sampled at 172 hours after the dose and was below the limit of detection when sampled at 316 hours after the infusion (Griffin, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue the drug or to discontinue breast-feeding should take into consideration the benefit of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Abraxane Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $1142.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F205651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (prior to day 1 of cycle for metastatic breast cancer and prior to days 1, 8, and 15 for NSCLC); hepatic function; monitor infusion site; monitor for neuropathy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abraxane (AU, CZ, DE, DK, EE, GB, IE, IN, NO, NZ, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Albumin-bound paclitaxel nanoparticle formulation; paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G",
"     <sub>",
"      2",
"     </sub>",
"     mitotic phase, and inhibiting cell replication. May also distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 632 L/m",
"     <sup>",
"      2",
"     </sup>",
"     (extensive extravascular distribution and/or tissue binding)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 89% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic primarily via CYP2C8 to 6-alpha-hydroxypaclitaxel; also to minor metabolites via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 27 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~20%); urine (4% as unchanged drug, &lt;1% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berveiller P, Vinot C, Mir O, et al, \"Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2012, 207(6):514.e1-514.e7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/23174392/pubmed\" id=\"23174392\" target=\"_blank\">",
"        23174392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman RL, Brady WE, McMeekin DS, et al, &ldquo;A Phase II Evaluation of Nanoparticle, Albumin-Bound (Nab) Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2011, 122(1):111-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/21497382/pubmed\" id=\"21497382\" target=\"_blank\">",
"        21497382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner ER, Dahut WL, Scripture CD, et al, &ldquo;Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(13):4200-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/18594000/pubmed\" id=\"18594000\" target=\"_blank\">",
"        18594000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gradishar WJ, Krasnojon D, Cheporov S, et al, &ldquo;Significantly Longer Progression-Free Survival With nab-paclitaxel Compared With Docetaxel as First-Line Therapy for Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(22):3611-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/19470941/pubmed\" id=\"19470941\" target=\"_blank\">",
"        19470941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gradishar WJ, Tjulandin S, Davidson N, et al, &ldquo;Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(31):7794-803.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/16172456 /pubmed\" id=\"16172456 \" target=\"_blank\">",
"        16172456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green MR, Manikhas GM, Orlov S, et al, &ldquo;Abraxane&reg;, a Novel Cremophor&reg;-Free, Albumin-Bound Particle Form of Paclitaxel for the Treatment of Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(8):1263-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/16740598/pubmed\" id=\"16740598\" target=\"_blank\">",
"        16740598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffin SJ, Milla M, Baker TE, et al, \"Transfer of Carboplatin and Paclitaxel into Breast Milk,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2012, 28(4):457-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/23087196/pubmed\" id=\"23087196\" target=\"_blank\">",
"        23087196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ibrahim NK, Samuels B, Page R, et al, &ldquo;Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(25):6019-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/16135470/pubmed\" id=\"16135470\" target=\"_blank\">",
"        16135470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nyman DW, Campbell KJ, Hersh E, et al, &ldquo;Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(31):7785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/16258082/pubmed\" id=\"16258082\" target=\"_blank\">",
"        16258082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizvi NA, Riely GJ, Azzoli CG, et al, &ldquo;Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel as Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(4):639-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/18235124/pubmed\" id=\"18235124\" target=\"_blank\">",
"        18235124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teneriello MG, Tseng PC, Crozier M, et al, &ldquo;Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1426-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/19224848/pubmed\" id=\"19224848\" target=\"_blank\">",
"        19224848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Hoff DD, Ramanathan RK, Borad MJ, et al, &ldquo;Gemcitabine Plus Nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(34):4548-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/29/8664/abstract-text/21969517/pubmed\" id=\"21969517\" target=\"_blank\">",
"        21969517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10159 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8664=[""].join("\n");
var outline_f8_29_8664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709192\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11571444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205694\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205675\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062244\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205676\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205677\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205695\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205653\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205641\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205655\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3137116\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205654\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7992223\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205701\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205692\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205658\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205643\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205647\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205669\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205649\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205659\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205684\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205660\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323591\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205651\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875318\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205642\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205657\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/24/22917?source=related_link\">",
"      Paclitaxel (nanoparticle albumin bound): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8665="Autoimmune complications following purine analog therapy";
var content_f8_29_8665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autoimmune complications following purine analog therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Jeffrey Zonder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8665/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/29/8665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine analogs have long been an important part of the treatment of hematologic malignancies. The adenosine analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has become perhaps the most widely used agent to treat chronic lymphocytic leukemia (CLL). Multiple cases of autoimmune hemolytic anemia (AIHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/1-5\">",
"     1-5",
"    </a>",
"    ] as well as autoimmune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/6-10\">",
"     6-10",
"    </a>",
"    ], apparently triggered by treatment with fludarabine treatment, have been reported.",
"   </p>",
"   <p>",
"    Autoimmune hemolytic anemia and immune thrombocytopenia (ITP) following the use of purine analogs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ) will be reviewed here. Infectious complications following purine analog therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, pathogenesis, diagnosis, and treatment of de novo autoimmune hemolytic anemia and de novo immune thrombocytopenia (ITP) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOIMMUNITY IN CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as one-third of patients with chronic lymphocytic leukemia (CLL) may develop AIHA over the course of their illness unrelated to treatment modality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/11\">",
"     11",
"    </a>",
"    ], although most series suggest a rate in the range of 4 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This background incidence of AIHA, particularly in patients with advanced stage CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/14\">",
"     14",
"    </a>",
"    ], makes the frequency of AIHA caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    difficult to estimate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CLL also have an increased incidence of immune-mediated (autoimmune) thrombocytopenia (AITP). The exact incidence of AITP in CLL is unknown, but it is thought to be somewhat lower than that of AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most of the reports of autoimmune hemolytic anemia (AIHA) following the use of purine analogs have been in patients with chronic lymphocytic leukemia (CLL), a few reports have noted AIHA following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    in two other indolent B-cell non-Hodgkin lymphomas, follicular lymphoma and Waldenstrom's macroglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     AIHA after fludarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report described 24 patients with CLL who developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -associated autoimmune hemolytic anemia (FA-AIHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/15\">",
"     15",
"    </a>",
"    ]. Twenty were identified through the Spontaneous Reporting System of the Food and Drug Administration, and the other four patients had been treated by the authors. Seventeen (71 percent) of the patients in this series developed AIHA during the first three cycles of fludarabine therapy, but in one case it occurred after six cycles. In six of the cases, the AIHA was also associated with autoimmune thrombocytopenia (ie, Evans syndrome). The median absolute decrease in the hematocrit due to the AIHA was 14 percent (range: 8 to 29 percent). Four patients died as a result of the initial episode of AIHA.",
"   </p>",
"   <p>",
"    Information available from large clinical trials suggests that treatment-related AIHA in CLL is uncommon, and, importantly, not limited to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . As examples:",
"   </p>",
"   <p>",
"    In a large French randomized trial comparing six monthly courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , adriamycin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CAP) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and prednisone (CHOP) as first-line therapy for patients with Binet stage B or C CLL 38 of 938 patients (4.0 percent) developed AIHA during or after assigned treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/16\">",
"     16",
"    </a>",
"    ]. The median duration of follow-up was 70 months, during which time 266 patients initially treated with CAP or CHOP received at least one cycle of fludarabine. While a statistically nonsignificant excess of AIHA was seen in the patients randomly assigned to treatment with CAP or CHOP as compared with those on the fludarabine arm (25 versus 13 cases), only three patients treated with CAP or CHOP developed AIHA during initial therapy, compared with six treated with fludarabine. Of the 22 other cases of AIHA in the",
"    <span class=\"nowrap\">",
"     CAP/CHOP",
"    </span>",
"    group, 20 occurred after subsequent treatment with fludarabine.",
"   </p>",
"   <p>",
"    In the British LRF CLL4 trial, patients with newly-diagnosed Binet stages A (progressive), B, and C CLL were randomly assigned to receive monthly cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , or fludarabine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and the incidences of a positive direct antiglobulin test (DAT, Coombs test) and AIHA were determined. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of a positive direct antiglobulin test (DAT) prior to treatment was 14 percent (89 of 637), whereas the incidence of clinical AIHA during treatment was 10 percent (77 of 759).",
"     </li>",
"     <li>",
"      AIHA developed in 8 percent of DAT-negative patients, and in 28 percent of DAT-positive patients.",
"     </li>",
"     <li>",
"      AIHA occurred in 12 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      , 11 percent in those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      alone, and 5 percent in those treated with fludarabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . Four deaths were attributed to AIHA during first-line treatment; all occurred in patients treated with fludarabine alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were seen in a retrospective analysis of more than 1200 patients treated at a single center over 10 years, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    therapy was not associated with an increased risk of developing AIHA, as compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/13\">",
"     13",
"    </a>",
"    ]. In this series, 52 cases of AIHA were observed, for a total incidence of 4.3 percent. Thirty-nine of these 52 patients had evidence of AIHA prior to receiving any systemic treatment for their CLL. Of the 13 episodes of AIHA occurring in treated patients, 10 were in patients who had previously been treated with chlorambucil plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CP), and only three had prior treatment with fludarabine plus prednisone (FP). The overall incidence of AHIA was 1.8 percent (10 of 559) in patients receiving CP, and 2.5 percent (3 of 121) in those receiving FP.",
"   </p>",
"   <p>",
"    In an evaluation of 310 patients treated with the FCR regimen, the MD Anderson group reported that 5.8 percent of patients developed AIHA during or following treatment. Of note is that most of these patients had a negative direct antiglobulin test (DAT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AIHA after cladribine or pentostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple reports of AHIA in CLL or other lymphoproliferative conditions triggered by therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/19-24\">",
"     19-24",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/25\">",
"     25",
"    </a>",
"    ]. In some instances, patients had a prior history of FA-AIHA.",
"   </p>",
"   <p>",
"    The small number of patients included in these reports, as well as the long time interval between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    exposure and development of AIHA in one of the reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/23\">",
"     23",
"    </a>",
"    ], makes assessment of causation problematic. Complicating this issue, there are also cases of CLL-associated AIHA that have been successfully treated with cladribine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/19,20,26\">",
"     19,20,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most evident risk factors for developing FA-AIHA are a positive direct antiglobulin test (DAT; Coombs test) and a prior history of FA-AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Development of a positive Coombs test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the LRF CLL4 trial noted above, of the 299 patients tested for DAT reactivity both before and after treatment, those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    alone, when compared with those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    or the",
"    <span class=\"nowrap\">",
"     fludarabine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    combination, were more likely to remain DAT positive (82 versus 52 and 42 percent, respectively) and to change from negative to positive (9 versus 3 and 4 percent, respectively).",
"   </p>",
"   <p>",
"    In several other reports, the DAT converted from negative prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    treatment to positive at the time AIHA was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In one instance, the DAT converted to positive after one cycle of fludarabine treatment without overt hemolysis, but the patient went on to develop fatal AIHA after three cycles of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the data from the LRF CLL4 trial, and the fact that only 38 of 130 patients with a positive DAT on a randomized French trial developed overt AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/16\">",
"     16",
"    </a>",
"    ], a positive DAT should not be considered a contraindication to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    therapy. Rather, patients with a DAT which is positive at the time of diagnosis or which becomes positive over the course of therapy should be watched with particular vigilance for any evidence of hemolysis. Alternatively, therapy with FC or FCR might be considered in such patients, as the reported incidence of AIHA appears to be somewhat lower than that with fludarabine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prior episode of FA-AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a prior history of FA-AIHA are at extremely high risk of recurrence of AIHA following retreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the studies mentioned above, eight patients with FA-AIHA who had their FA-AIHA resolved with corticosteroid therapy were rechallenged with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ; seven had a recurrence of AIHA, three of which ended fatally [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A group of Australian investigators retreated 8 of 12 patients with CLL who developed FA-AIHA with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ; AIHA recurred in six [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrence of AIHA triggered by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      after prior FA-AIHA has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OF FA-AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The varying rates of autoimmunity and the apparent paradoxical improvement in some cases of AIHA following purine analog therapy may be in part explained by the profound suppressive effect of this class of drugs on T-cell subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/14,29\">",
"     14,29",
"    </a>",
"    ]. Depletion of specific subsets of T-helper cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/30\">",
"     30",
"    </a>",
"    ] and the potential effect this could have on cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/31\">",
"     31",
"    </a>",
"    ] may result in a \"permissive\" environment for the development of autoimmune conditions in some cases, whereas in others it might alter the balance of T-cell function such that any tendency towards autoimmunity is reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Genesis of antibody production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no clinical trials formally examining treatment of FA-AIHA in patients with CLL. However, measures similar to those taken for the treatment of idiopathic autoimmune warm hemolytic anemia should be taken. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      should be discontinued immediately upon recognition of AIHA. Supportive red blood cell transfusions are critical for patients in whom severe hemolysis develops.",
"     </li>",
"     <li>",
"      Corticosteroids are a key part of treatment, typically administered at oral doses equivalent to 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . AIHA will often begin to improve within a few days, although delayed responses can be seen. After AIHA has improved, corticosteroids are typically tapered over a period of several weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Poorly responsive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of options are available for the treatment of poorly-responsive FA-AIHA. These include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A (CSA) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be added to steroids if the response is suboptimal after a week or more of therapy. The starting dose of CSA is 5 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses, adjusted thereafter to keep the trough levels at approximately 100",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/32\">",
"     32",
"    </a>",
"    ]. Azathioprine is started at 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally, and may be increased up to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day after four weeks if no response is seen. The starting dose of azathioprine in one case report of successfully-treated FA-AIHA was 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/33\">",
"     33",
"    </a>",
"    ]. Unfortunately, neither of these agents is universally effective in controlling AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative systemic chemotherapy may sometimes effectively control FA-AIHA, even in the absence of an objective response of the underlying leukemia. In a retrospective analysis of 1203 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    induced partial or complete remissions in two-thirds of patients with FA-AIHA, a response rate similar to that observed for de novo AIHA in CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) as treatment of AIHA should be used cautiously, as they may, in some cases, suppress the compensatory reticulocytosis without arresting the ongoing hemolysis, thereby aggravating the anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    (2-CdA) is another purine analogue which has been used as therapy for patients with CLL and AIHA, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    - associated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/19,34\">",
"     19,34",
"    </a>",
"    ] or de novo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/20,26,35\">",
"     20,26,35",
"    </a>",
"    ]. AIHA may improve after 2-CdA therapy even when the CLL does not respond [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/26\">",
"     26",
"    </a>",
"    ]. Treatment with 2-CdA can occasionally precipitate a relapse of AIHA in individuals with prior FA-AIHA, necessitating careful surveillance of patients receiving this agent (see",
"    <a class=\"local\" href=\"#H5\">",
"     'AIHA after cladribine or pentostatin'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports, as well as the encouraging experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for autoimmune cytopenias associated with other B-cell lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], demonstrate usefulness of rituximab as treatment of AIHA. Rituximab, 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly for four consecutive weeks, has been used successfully to treat a case of FA-AIHA refractory to corticosteroids. One study treated a patient with FA-AIHA with rituximab, with resolution of hemolysis lasting over a year at the time of the report [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/39\">",
"     39",
"    </a>",
"    ]. Two other studies reported cases of AIHA (not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -associated) in patients with CLL with responses to a single four-week course of rituximab lasting three years, one year, and three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Monoclonal antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another group of investigators used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to treat AIHA in two patients with CLL (previously treated with alkylator-based chemotherapy) and one case of prolymphocytic leukemia previously treated with alkylators as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . All three patients had complete responses of their AIHA lasting 8 to 20 months after one course of rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a separate study, eight patients with AIHA and CLL were treated with a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (RCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/43\">",
"     43",
"    </a>",
"    ]. Six of the eight patients in this report had received prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and all eight of the patients had a complete resolution of their AIHA after treatment with RCD. A subsequent report described successful outcomes in all 20 patients with CLL and AIHA treated with this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, in one study, no hemolytic crisis was seen in eight patients with CLL and preexisting AIHA who were treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (FCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of cases, the anti CD52 antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , has been successfully used to treat patients with AIHA. In a series of five patients with CLL-associated AIHA, four of whom had previously been treated with chemotherapy that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , all responded to subcutaneous administration of alemtuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/45\">",
"     45",
"    </a>",
"    ]. Responses were durable, with no relapses of AIHA after a median of 12 months of follow-up. The same group reported a case of severe FA-AIHA, which resolved and had not recurred after 15 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/46\">",
"     46",
"    </a>",
"    ]. It is important to keep in mind that alemtuzumab can be associated with prolonged immunosuppression, with the resultant risk of life-threatening infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin has been shown to be efficacious in a minority of patients not responding adequately to steroids. As in the case of de novo warm autoantibody- mediated AIHA, IVIG dosages of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    or higher may be necessary, sometimes with the need for subsequent retreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Intravenous gamma globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is typically considered for patients in whom the above measures have failed, occasionally providing long-term control of AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Retreatment with fludarabine or other chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of FA-AIHA have a very high risk of recurrent AIHA if rechallenged with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. However, in these two series, there were patients who did not develop AIHA upon reexposure, suggesting that if other treatment options are lacking for a patient with progressive CLL, fludarabine might be utilized with caution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study described a patient with FA-AIHA that responded to corticosteroids and did not recur with subsequent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      retreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another patient with CLL and a history of FA-AIHA was successfully retreated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      as part of the induction regimen for a reduced intensity allogeneic stem cell transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/52\">",
"       52",
"      </a>",
"      ]. Treatment included total body irradiation (200 cGy),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      A,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and intravenous immunoglobulin as part of his peritransplant therapy. It is possible that the intensive immunosuppressive effects of this regimen could have facilitated tolerance to fludarabine rechallenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether agents administered concurrently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    affect the likelihood of recurrent FA-AIHA. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 60 previously untreated patients with CLL who received sequential",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , there were no cases of AIHA [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although previously untreated patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (flu-cy) arm of the LRF CLL4 trial described above had a lower rate of AIHA than those treated with either fludarabine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/17\">",
"       17",
"      </a>",
"      ], there are no data available regarding AIHA from the largest American studies of either flu-cy or flu-cy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in previously-treated CLL [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study of 300 patients treated with the combination of flu-cy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FCR) as initial therapy for CLL, the combined incidence of AIHA and pure red cell aplasia was 6.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/18,56\">",
"       18,56",
"      </a>",
"      ], a rate similar to that reported for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      alone. Based on the results in a relatively small number of patients, the authors concluded that the FCR regimen can be given safely to patients with pre-existing AIHA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, there are insufficient data to prove that adding either alkylating agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    concurrently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    makes rechallenge safer in patients with a history of FA-AIHA, although the available data suggest that these regimens are likely to be preferable to the use of fludarabine alone. Since there are other reports of AIHA precipitated by alkylating agents which predate the advent and use of fludarabine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/57\">",
"     57",
"    </a>",
"    ], close monitoring is prudent in patients undergoing any type of subsequent therapy if there is a history of FA-AIHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL also have an increased incidence of immunologically-mediated (autoimmune) thrombocytopenia (AITP). The exact incidence of AITP in CLL is unknown, but it is thought to be somewhat lower than that of AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/14\">",
"     14",
"    </a>",
"    ]. Only anecdotal experience is available on this point. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three of 21 patients with CLL who were treated at the National Cancer Institute developed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -associated AITP (FA-AITP) within the first three cycles of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others have described episodes of FA-AITP occurring in patients with CLL or other lymphoproliferative diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/7-10\">",
"       7-10",
"      </a>",
"      ], and we have seen one case, as well.",
"     </li>",
"     <li>",
"      In one report, one of two patients had recurrences of AITP upon each of two subsequent re-exposures to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , indicating a causative effect of fludarabine in this case [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because serologic testing for AITP is less reliable than for AIHA, when a patient with CLL develops thrombocytopenia, a bone marrow evaluation is often necessary to distinguish AITP from either disease-related or myelosuppression-induced thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once diagnosed, treatment of FA-AITP may not be immediately required, unless the platelet counts are severely depressed (ie,",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient is experiencing bleeding. Treatment options for FA-AITP are similar to those for FA-AIHA and non-drug-related immune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/6,58\">",
"     6,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment of FA-AIHA'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with FA-AIHA, despite the fact that several cases of AITP appear to have been triggered by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    therapy, there are case reports of CLL patients with AITP that improved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/26\">",
"     26",
"    </a>",
"    ] or resolved completely [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/59\">",
"     59",
"    </a>",
"    ] after purine analogue therapy. Since there is a paucity of information available regarding the use of other purine analogues after development of FA-AITP, it is prudent to use other classes of agents when possible as treatment of either progressive CLL or recurrent AITP in patients with a history strongly suggestive of FA-AITP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE NEUTROPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune neutropenia following treatment of CLL with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    is extremely rare. Only a few cases have been reported; one was associated with the presence of anti-neutrophil autoantibodies, and one with a maturation arrest of the granulocyte series at the promyelocyte stage in the absence of demonstrable anti-neutrophil antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      -associated autoimmune hemolytic anemia &mdash; The diagnosis of this condition is made in a patient with chronic lymphocytic leukemia or other indolent lymphoma who develops hemolytic anemia, not always in association with a positive Coombs test (DAT) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8665/abstract/18\">",
"       18",
"      </a>",
"      ], following the use of a purine analog, most commonly fludarabine (FA-AIHA).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This condition may recur when a patient with a prior diagnosis of FA-AIHA is retreated with the same or a different purine analog, or following the use of a different chemotherapeutic agent (eg, alkylating agent). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      -associated immune thrombocytopenia &mdash; The diagnosis of this condition (FA-AITP), which is less common than FA-AIHA, is made in a patient with chronic lymphocytic leukemia or other indolent lymphoma who develops immune thrombocytopenia following the use of a purine analog, most commonly fludarabine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Clinically apparent associated conditions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend as initial treatment of FA-AIHA or FA-AITP that the purine analog be immediately discontinued, followed by the institution of corticosteroids, at oral doses equivalent to 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial steps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized studies to help in the decision as to which",
"      <span class=\"nowrap\">",
"       agent/agents",
"      </span>",
"      to use in the case of poorly responsive FA-AIHA or FA-AITP. We suggest that such patients be treated the same as patients with poorly responsive de novo AIHA or ITP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Poorly responsive disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H31#H31\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have had a prior diagnosis of FA-AIHA or FA-AITP who require additional chemotherapy, we suggest that purine analogs not be employed as single agents if at all possible, and, if used in combination regimens such as FCR, employed with extreme caution (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Regardless of the drug chosen for this purpose, the patient's hematologic status should be monitored carefully, and the agent discontinued at the first evidence for recurrence of this complication. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Retreatment with fludarabine or other chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/1\">",
"      Tertian G, Cartron J, Bayle C, et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/2\">",
"      Tsiara S, Christou L, Konstantinidou P, et al. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol 1997; 54:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/3\">",
"      Longo G, Gandini G, Ferrara L, et al. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia. Eur J Haematol 1997; 59:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/4\">",
"      Taha HM, Narasihman P, Venkatesh L, et al. Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders. Am J Hematol 1998; 59:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/5\">",
"      Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/6\">",
"      Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/7\">",
"      Leach M, Parsons RM, Reilly JT, Winfield DA. Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders. Clin Lab Haematol 2000; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/8\">",
"      Bay JO, Fouassier M, B&eacute;al D, et al. Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia. Hematol Cell Ther 1997; 39:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/9\">",
"      Churn M, Clough V. Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma. Clin Oncol (R Coll Radiol) 2001; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/10\">",
"      Usman M, Adil SN, Sajid R, Khurshid M. Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia. J Pak Med Assoc 2003; 53:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/11\">",
"      Bergsagel DE. The chronic leukemias: a review of disease manifestations and the aims of therapy. Can Med Assoc J 1967; 96:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/12\">",
"      D&uuml;hrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/13\">",
"      Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95:2786.",
"     </a>",
"    </li>",
"    <li>",
"     Hamblin T. Autoimmune Disease and Its Management in Chronic Lymphocytic Leukemia. In: Chronic Lymphoid Leukemias, Cheson B (Ed), Marcel Dekker, New York 2001. p.435.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/15\">",
"      Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/16\">",
"      Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/17\">",
"      Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008; 111:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/18\">",
"      Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 2007; 136:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/19\">",
"      Chasty RC, Myint H, Oscier DG, et al. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leuk Lymphoma 1998; 29:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/20\">",
"      Robak T, Basiska-Morawiec M, Krykowski E, et al. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997; 58:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/21\">",
"      Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 1995; 48:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/22\">",
"      Robak T, Boski JZ, Kasznicki M, et al. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. Eur J Haematol 2002; 69:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/23\">",
"      Tetreault SA, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstr&ouml;m macroglobulinemia. Leuk Lymphoma 2000; 37:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/24\">",
"      Aslan DL, Peterson BA, Long-Tsai M, Eastlund T. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenstr&ouml;m's macroglobulinemia. Transfusion 2006; 46:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/25\">",
"      Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/26\">",
"      Zaucha JM, Haaburda K, Ciepuch H, Hellmann A. 2-Chlorodeoxyadenosine treatment of patients with chronic lymphocytic leukaemia associated with autoimmune haemolysis. Acta Haematol Pol 1994; 25:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/27\">",
"      Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/28\">",
"      Orchard J, Bolam S, Myint H, et al. In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol 1998; 102:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/29\">",
"      Dighiero G. Adverse and beneficial immunological effects of purine nucleoside analogues. Hematol Cell Ther 1996; 38 Suppl 2:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/30\">",
"      Peller S, Kaufman S. Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: correlation with disease stage. Blood 1991; 78:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/31\">",
"      Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL-10/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA). Autoimmunity 2002; 35:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/32\">",
"      Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/33\">",
"      Tosti S, Caruso R, D'Adamo F, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 1992; 65:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/34\">",
"      Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/35\">",
"      Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/36\">",
"      Trap&egrave; G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003; 88:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/37\">",
"      Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 2003; 44:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/38\">",
"      Hofer S, Hunziker S, Dirnhofer S, Ludwig C. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. Br J Haematol 2003; 122:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/39\">",
"      Paydas S. Fludarabine-induced hemolytic anemia: successful treatment by rituximab. Hematol J 2004; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/40\">",
"      Shvidel L, Shtalrid M, Berrebi A. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by Rituximab. Leuk Lymphoma 2004; 45:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/41\">",
"      Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002; 69:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/42\">",
"      Iannitto E, Ammatuna E, Marino C, et al. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood 2002; 99:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/43\">",
"      Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/44\">",
"      Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/45\">",
"      Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/46\">",
"      Lundin J, Karlsson C, Celsing F. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol 2006; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/47\">",
"      Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003; 70:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/48\">",
"      Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/49\">",
"      Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/50\">",
"      Bj&ouml;rkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 1993; 234:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/51\">",
"      Bastion Y, Coiffier B, Dumontet C, et al. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/52\">",
"      Ford CD, Asch J, Pulsipher M, Petersen FB. Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia. Br J Haematol 2004; 126:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/53\">",
"      Del Poeta G, Del Principe MI, Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005; 104:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/54\">",
"      O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/55\">",
"      Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/56\">",
"      Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/57\">",
"      Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible \"trigger\" mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol 1966; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/58\">",
"      Seipelt G, B&ouml;hme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001; 80:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/59\">",
"      Wells T, Kovacs MJ. Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine. Ann Pharmacother 2003; 37:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/60\">",
"      Stern SC, Shah S, Costello C. Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia. Br J Haematol 1999; 106:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8665/abstract/61\">",
"      Roberts L, Lucas G, Green L, et al. Autoimmune neutropenia following therapy for chronic lymphocytic leukaemia: a report of three cases. Br J Haematol 2007; 136:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7141 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8665=[""].join("\n");
var outline_f8_29_8665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOIMMUNITY IN CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AUTOIMMUNE HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AIHA after fludarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AIHA after cladribine or pentostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Development of a positive Coombs test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prior episode of FA-AIHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OF FA-AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Poorly responsive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cladribine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Retreatment with fludarabine or other chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AUTOIMMUNE THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      AUTOIMMUNE NEUTROPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8666="Determination of initial therapy in patients with multiple myeloma";
var content_f8_29_8666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Determination of initial therapy in patients with multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8666/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8666/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/29/8666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/29/8666/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/29/8666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1062479\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of initial diagnosis every effort should be made to distinguish multiple myeloma (MM) from its premalignant stages, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Patients with MM require therapy, whereas for patients with MGUS and SMM, the standard of care is observation alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of MM is verified, the choice of initial therapy is affected by two main factors: risk-stratification and eligibility for autologous hematopoietic cell transplantation (HCT). The choice of therapy in a newly diagnosed patient is important since it may affect the type of treatment options patients can have in the future. For example, alkylating agents are among our best chemotherapeutics for MM, but their use limits the ability to collect peripheral stem cells for autologous HCT.",
"   </p>",
"   <p>",
"    This topic reviews the three main considerations in any potential patient with newly diagnosed MM, namely verification of the diagnosis, risk stratification, and eligibility for HCT. The overall treatment strategy and a review of the available options are also summarized here. The specific initial chemotherapy options for symptomatic multiple myeloma patients based upon risk stratification and transplant eligibility are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of HCT in MM, chemotherapy in patients with relapsed or resistant MM, the treatment of complications of MM (eg, hypercalcemia, renal insufficiency, skeletal lesions), and the use of bisphosphonates in MM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VERIFICATION OF THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in approaching a potential new patient with MM is to verify the diagnosis since the premalignant stages of myeloma, namely MGUS and SMM, do not require therapy and may be easily misdiagnosed as multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1899117\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy of undetermined significance (MGUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MGUS have a monoclonal protein less than 3",
"    <span class=\"nowrap\">",
"     gm/dL,",
"    </span>",
"    less than 10 percent clonal plasma cells on bone marrow biopsy, and no evidence of end organ damage (anemia, hypercalcemia, lytic bone lesions or renal failure) that can be attributed to the underlying plasma cell proliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In contrast, patients with multiple myeloma must have end organ damage that is felt to be related to the underlying plasma cell disorder. Patients with MGUS can be misdiagnosed as multiple myeloma if one is not careful. For example, patients with MGUS can have renal failure due to unrelated disorders such as diabetes or hypertension, or may have bone lesions from other cancers. Therefore every effort should be made to determine whether the observed &ldquo;end organ damage&rdquo; is truly secondary to the underlying plasma cell disorder and not another unrelated process. Patients with MGUS require no therapy. The risk of progression to multiple myeloma or related plasma cell disorder is only 1 percent per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Smoldering (asymptomatic) multiple myeloma (SMM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SMM is defined as an M-protein &ge;3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &ge;10 percent bone marrow plasma cells but no end organ damage (lytic lesions, anemia, renal disease, or hypercalcemia) that can be attributed to the underlying plasma cell disorder (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. SMM is differentiated from MGUS based on the size of the M protein and the level of bone marrow involvement. It is considered as a separate premalignant entity because the risk of progression is much higher than with MGUS (10 percent per year versus 1 percent per year, respectively). As a result, patients with SMM need more frequent follow-up compared with MGUS, every three to four months versus once a year, respectively. While initial definitions of SMM did not include an upper limit of bone marrow involvement, subsequent studies have demonstrated that patients with &ge;60 percent plasma cells in the bone marrow have a clinical course characterized by progression to symptomatic myeloma within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As such, asymptomatic patients with bone marrow involvement &ge;60 percent may be managed in a similar fashion to patients with symptomatic myeloma rather than as SMM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike patients with multiple myeloma, patients with SMM do not have any evidence of end organ damage that can be attributed to the underlying plasma cell disorder. SMM needs to be differentiated from multiple myeloma because patients with SMM do not require immediate treatment. As with MGUS, patients with SMM can be misdiagnosed as multiple myeloma, and there is absence of clear benefit with currently available therapies, and some patients with SMM can remain stable without treatment over extended periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/3,8-11\">",
"     3,8-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Among patients with smoldering myeloma, we recommend close follow-up with deferral of chemotherapy until progression to symptomatic disease. A clearly increasing level of the M-protein in the serum or urine suggests that therapy will be needed in the near future. Details on the prognostic value of end organ damage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Smoldering multiple myeloma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10618?source=see_link\">",
"     \"Staging and prognostic studies in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This decision to delay therapy in patients with SMM is supported by a 2003 Cochrane meta-analysis compared chemotherapy at diagnosis to deferral of chemotherapy until progression in 262 SMM patients enrolled in three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/9\">",
"     9",
"    </a>",
"    ]. While early treatment delayed progression of the disease (odds ratio [OR] of 0.16, 95% CI 0.09-0.29), there were no significant effects on mortality or response rate and early treatment may increase the risk of acute leukemia (OR 3.20, 95% CI 0.55-18.73). A preliminary report from another randomized trial evaluating the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients at high risk of progression also suggests that early treatment can delay the onset of symptomatic disease, but additional follow-up will be required to assess the long-term impact of this combination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with smoldering myeloma will progress to symptomatic myeloma or AL amyloidosis at an approximate rate of 10 percent per year for the first five years, 3 percent per year for the next five years, and 1 to 2 percent per year for the following 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/4\">",
"     4",
"    </a>",
"    ]. As such, the majority of patients with SMM will progress with a median time to progression of 4.8 years. Factors associated with an increased risk of progression include an abnormal free light chain ratio (&lt;0.125 or &gt;8.0), bone marrow plasma cells &ge;10 percent, and a serum M protein &ge;3",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Our approach to follow-up is similar to that suggested by the International Myeloma Working Group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/13\">",
"     13",
"    </a>",
"    ]. At the time of diagnosis, we perform a serum protein electrophoresis (SPEP), complete blood count (CBC), serum creatinine, serum calcium, urine protein electrophoresis (UPEP) with immunofixation, bone marrow biopsy, skeletal survey, and magnetic resonance imaging (MRI) of the spine and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/13\">",
"     13",
"    </a>",
"    ]. Two to three months after this testing, we again measure the SPEP, CBC, creatinine, calcium, UPEP, and urine immunofixation. If the results of these tests are stable, the span of time between testing can be lengthened to every 4 to 6 months for one year, then to every 6 to 12 months. A metastatic bone survey is recommended annually because asymptomatic bone lesions may develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Smoldering multiple myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with MGUS and SMM patients, patients with multiple myeloma (MM) require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/14\">",
"     14",
"    </a>",
"    ]. Without effective therapy, symptomatic patients die within a median of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings of end organ damage, if attributable to the underlying plasma cell disorder, define the presence of multiple myeloma and are clear indications for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia (ie, hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      below normal)",
"     </li>",
"     <li>",
"      Hypercalcemia (ie, serum calcium &gt;11.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.875",
"      <span class=\"nowrap\">",
"       mmol/liter])",
"      </span>",
"     </li>",
"     <li>",
"      Renal insufficiency (ie, serum creatinine &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [176.8",
"      <span class=\"nowrap\">",
"       &micro;mol/liter])",
"      </span>",
"     </li>",
"     <li>",
"      Lytic bone lesions or severe osteopenia",
"     </li>",
"     <li>",
"      Extramedullary plasmacytoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with &ge;60 percent clonal plasma cells in the bone marrow who lack end-organ damage are also considered as having MM and are candidates for initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with MM as defined above need therapy. However, if there is doubt about whether the patient has SMM or MM, the most reasonable approach is to reevaluate the patient in two months and to delay therapy until the correct diagnosis is evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis in myeloma depends on several variables: host factors (age, performance status, co-morbidities); stage; response to therapy; and disease biology. Disease biology is dictated by the underlying cytogenetic abnormalities in the myeloma clone. It is a major predictor of outcome and also influences the choice of therapy to some extent. Thus, all myeloma patients are risk-stratified at initial diagnosis based on fluorescence in situ hybridization (FISH) studies on the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If FISH is unavailable, conventional cytogenetics can be used as an alternative but is much less sensitive.",
"   </p>",
"   <p>",
"    We recommend that at least one of the following tests, preferably FISH, be performed to assess risk in all newly diagnosed patients (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conventional cytogenetics (karyotyping) for detection of del 13, monosomy 13, or hypodiploidy",
"     </li>",
"     <li>",
"      FISH for detection of t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disease staging and prognosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10618?source=see_link&amp;anchor=H5#H5\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Prognostic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2601852\">",
"    <span class=\"h2\">",
"     High risk myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with t(14;16), t(14;20), or del17p13 by FISH account for approximately 15 percent of MM and are considered to have high risk MM [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These patients have a median survival of approximately two to three years despite standard treatment. Patients with a high risk signature on gene expression profiling are also considered to have high risk MM, but this test is not recommended on a routine basis. The presence of trisomies in patients with high risk cytogenetics may ameliorate some of the adverse prognostic effect of high risk cytogenetic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2601859\">",
"    <span class=\"h2\">",
"     Intermediate risk myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with t(4;14) by FISH or deletion",
"    <span class=\"nowrap\">",
"     13/hypodiploidy",
"    </span>",
"    by conventional cytogenetics were previously considered to have high risk disease, but with appropriate therapy (early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -containing regimens and hematopoietic cell transplantation), patients with these findings have outcomes approaching that of standard risk myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These patients are therefore now considered as having intermediate risk MM. (See",
"    <a class=\"local\" href=\"#H20047776\">",
"     'Treatment of standard or intermediate risk myeloma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2601866\">",
"    <span class=\"h2\">",
"     Standard risk myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with MM who lack any of the high or intermediate risk genetic abnormalities described above are considered to have standard risk MM. This includes patients with trisomies t(11;14) and t(6;14) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20047776\">",
"     'Treatment of standard or intermediate risk myeloma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial therapy of patients with symptomatic myeloma varies depending on whether patients are eligible or not to pursue autologous HCT (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"     algorithm 2",
"    </a>",
"    ). The specific choices for initial therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DETERMINING TRANSPLANT ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As will be described below, autologous hematopoietic cell transplantation (HCT) results in superior event-free and overall survival rates when compared with combination chemotherapy. As such, all patients should be evaluated at diagnosis for transplant eligibility so that the risks and benefits of autologous HCT can be reviewed with those eligible.",
"   </p>",
"   <p>",
"    A minority of patients will be eligible for allogeneic HCT, but the role of allogeneic approaches in myeloma remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility for autologous HCT in MM varies across countries and institutions. In most European countries, transplantation for myeloma is offered primarily to patients less than 65 years of age. In the United States, a strict age-limit is not used. Instead, decisions are made on a case-by-case basis based upon \"physiologic age\" and vary across institutions.",
"   </p>",
"   <p>",
"    In most centers in the United States, patients with one or more of the following factors are not considered eligible for autologous HCT in myeloma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &gt;77 years",
"     </li>",
"     <li>",
"      Direct bilirubin &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"     </li>",
"     <li>",
"      Serum creatinine &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"      unless on chronic stable dialysis",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 unless due to bone pain (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New York Heart Association functional status Class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are guidelines and the decision on transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. Whether newer chemotherapeutic programs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) will result in a reduced need for HCT is not known at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Age and disease stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most centers have excluded patients over the age of 70 due to concerns that they would not be able to withstand the potentially greater toxicity incurred with myeloablative regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/22\">",
"     22",
"    </a>",
"    ]. However, advances in supportive care have made autologous HCT feasible in older patients, assuming they have no other medical problems that would preclude high dose therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a description of three retrospective studies that have investigated the impact of age on outcomes after HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated survival after transplantation in patients over the age of 70 (mean age: 72, range: 70 to 83) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/24\">",
"       24",
"      </a>",
"      ]. Complete remission was achieved in 20 and 27 percent after a single or tandem (double) autologous transplant, respectively, with median overall survivals of 13 and 33 months. Treatment-related mortality was 16 percent in patients receiving 200",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , 2 percent in subsequent patients receiving 140",
"      <span class=\"nowrap\">",
"       mg/m2,",
"      </span>",
"      and 10 percent for those undergoing a tandem transplant.",
"     </li>",
"     <li>",
"      Another retrospective study of patients undergoing tandem (double) autologous transplants compared 49 patients age 65 years or older to 49 younger patients matched for other known prognostic factors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/25\">",
"       25",
"      </a>",
"      ]. Although the incidence of CR was lower in the older patients (20 versus 43 percent), age was not a predictor of worse outcomes; CR duration, event-free survival, and overall survival were comparable in the two groups. The prognosis was primarily determined by the presence of unfavorable cytogenetics (11q breakpoints, monosomy 13 or deletion 13q, or any translocation) and serum beta-2 microglobulin &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"     </li>",
"     <li>",
"      Another matched pairs analysis that included 33 patients &ge;70 years and 60 patients &le;65 years at the time of HCT reported similar overall response rates (approximately 97 percent) and median time to progression (approximately 23 months) for the two age groups [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/26\">",
"       26",
"      </a>",
"      ]. Although many patients in the older group received dose-reduced",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      as their conditioning regimen, the toxicity of and outcomes with HCT appear similar to those for the younger group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the Centers for Medicare and Medicaid Services approves reimbursement for high-dose therapy with autologous HCT in newly-diagnosed patients with myeloma who are less than 78 years old and have Durie-Salmon stage II or III disease, and for selected patients who have been previously treated. Additional details are available on the Centers for Medicare and Medicaid Services website at:",
"    <a class=\"external\" href=\"file://www.cms.gov/\">",
"     www.cms.gov",
"    </a>",
"    . Dose adjustment of the induction regimen is often necessary for older adults undergoing HCT. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H11#H11\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the older patient with multiple myeloma, thus permitting the formulation of an appropriate, individualized treatment plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal failure increases the morbidity and mortality of myeloma, it appears to have no adverse effect on either the quality of stem cell collection or engraftment following autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/27\">",
"     27",
"    </a>",
"    ]. In a study of patients with multiple myeloma and a serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    undergoing autologous HCT, median overall survival for the entire group of 81 patients was &gt;53 months; there was a median survival of &gt;51 months for the 38 patients who were dialysis-dependent. In this study, only two dialysis patients recovered partial renal function post-transplant, while in a second study four of 17 evaluable patients became dialysis-independent at a median time of five months post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The randomized trials that have shown benefit with HCT compared with chemotherapy have mainly studied patients with serum creatinine &lt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    HCT in patients with renal failure must therefore be approached with caution. The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    used as the conditioning regimen should be reduced to 140",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    in patients with serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Renal function can also be used to determine eligibility for an outpatient HCT. In our experience and that of others, more than one-half of patients with a serum creatinine &lt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    (or &lt;3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [265",
"    <span class=\"nowrap\">",
"     &micro;mol/liter])",
"    </span>",
"    can undergo HCT as an outpatient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with autologous hematopoietic cell transplantation (HCT), eligibility for allogeneic HCT varies across countries and institutions. Allogeneic HCT requires hematopoietic cells from a HLA-matched donor, which are given after the patient receives high dose chemotherapy and total body radiation. Only 5 to 10 percent of patients with multiple myeloma are candidates for this approach, with the remainder being excluded because of age, lack of an HLA-matched sibling donor, or inadequate renal, pulmonary or cardiac function.",
"   </p>",
"   <p>",
"    As discussed in more detail below, the role of allogeneic transplantation in myeloma remains investigational. Conventional myeloablative allogeneic transplantation is generally not recommended in myeloma outside the setting of a clinical trial for most patients due to unacceptably high transplant related mortality and lack of good evidence that such an approach is superior to current therapy. The treatment related mortality rate is lower with non-myeloablative conditioning (reduced intensity conditioning), but except in high risk patients such therapy should also be largely considered investigational.",
"   </p>",
"   <p>",
"    In most centers in the United States, patients are considered eligible for non-myeloablative allogeneic HCT only if they are less than 65 years of age, with normal cardiac, liver, and renal function, and in good performance status (ECOG performance status 0 or 1) (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    ). For a conventional myeloablative transplantation, eligibility is more restrictive in that patients should typically be less than 60 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20047776\">",
"    <span class=\"h1\">",
"     TREATMENT OF STANDARD OR INTERMEDIATE RISK MYELOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of transplant candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients receive induction therapy. The type can vary based on whether the patient is eligible for transplantation (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent treatment options for patients with standard or intermediate risk MM who are eligible for HCT include chemotherapy alone, high dose chemotherapy followed by autologous HCT and high dose chemotherapy followed by allogeneic HCT. Among these, high dose chemotherapy followed by autologous HCT (administered early or delayed at the time of first relapse) is associated with the highest survival rates, with chemotherapy alone being inferior. However, as newer agents are incorporated into the initial treatment of MM, the role of HCT may change. Although allogeneic HCT offers the only chance at cure, it is less desirable because of its high early mortality rates.",
"   </p>",
"   <p>",
"    In general, the preferred approach is therefore high dose chemotherapy followed by early or delayed autologous HCT. For select patients, a second autologous HCT, performed shortly after the first may be of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Autologous HCT versus chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting data exist concerning the survival benefit with autologous HCT versus chemotherapy alone. The best designed randomized studies report that autologous HCT is associated with superior event-free survival and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. By comparison, many of the studies that did not show a survival benefit from HCT are relatively flawed since the results failed to distinguish survival with HCT for initial therapy from survival with HCT for relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/32,35-40\">",
"     32,35-40",
"    </a>",
"    ]. This limitation likely minimized the benefit seen with initial HCT in these studies.",
"   </p>",
"   <p>",
"    The following are details concerning the two best designed trials showing survival benefits with autologous HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional dose chemotherapy was compared with high-dose therapy followed by autologous HCT in 401 previously untreated patients with myeloma &lt;65 years of age in a prospective, randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/32\">",
"       32",
"      </a>",
"      ]. A small percentage of patients in the chemotherapy alone arm underwent autologous (15 percent) or allogeneic (2 percent) HCT at the time of relapse. At a median follow-up of 42 months, intention-to-treat analysis showed that high-dose therapy followed by autologous HCT significantly increased median survival by one year (54 versus 42 months).",
"     </li>",
"     <li>",
"      The IFM 90 randomized trial compared high dose chemotherapy supported by autologous HCT with conventional chemotherapy alone in 200 previously untreated patients with myeloma under the age of 65 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/31,33\">",
"       31,33",
"      </a>",
"      ]. Of note, 25 percent of the patients randomly assigned to the HCT arm did not undergo HCT and nine patients from the conventional chemotherapy arm underwent HCT at relapse. An intention-to-treat analysis demonstrated the following significantly better outcomes with HCT (",
"      <a class=\"graphic graphic_figure graphicRef64033 \" href=\"UTD.htm?39/46/40685\">",
"       figure 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Higher overall (81 versus 57 percent) and complete (22 versus 5 percent) response rates",
"     </li>",
"     <li>",
"      Higher rates of seven year event-free (16 versus 8 percent) and overall survival (43 versus 25 percent)",
"     </li>",
"     <li>",
"      Longer median overall survival (57 versus 44 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the overall survival benefit seen in a few randomized trials and the marked limitations of the studies that failed to show a benefit, we believe that there is a significant survival benefit to autologous HCT when compared with chemotherapy alone. Despite this, there are limitations to the data supporting this recommendation. Since these trials were conducted, newer agents that are highly active in MM, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , have become available. Even with the availability of these agents, chemotherapy is not curative of MM and eligible patients will require a HCT at some point in their disease course. For patients who are considered candidates for HCT, we recommend induction therapy followed by autologous HCT (early or at time of first relapse depending on risk stratification) rather than conventional chemotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Double HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the survival benefits observed with autologous HCT, it has been postulated that even more intensive chemotherapy followed by an additional HCT, a procedure termed double (tandem)-autologous HCT, may offer even better outcomes. Several randomized and non-randomized trials have evaluated the relative efficacy of double versus single autologous HCT in previously untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/8,41-53\">",
"     8,41-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the randomized trials, consistent benefits have primarily been reported among those with less than a very good partial response (VGPR) to the initial transplant procedure. This was shown in the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 399 previously untreated patients &lt;60 years of age were randomly assigned to either single or double autologous HCT, in which the preparative regimens were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      140",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      plus TBI for the first transplant and melphalan 140",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      alone for the second [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/50\">",
"       50",
"      </a>",
"      ]. The following results were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among all patients, there was significantly improved seven-year event-free survival (20 versus 10 percent) and overall survival (42 versus 21 percent) in recipients of double versus single autologous HCT.",
"     </li>",
"     <li>",
"      The beneficial effect of the second transplant on overall survival differed according to the response to the first transplant. Patients who achieved a complete response (CR) or VGPR with the first HCT did not benefit significantly from the second transplant. By comparison, patients who did not have at least a VGPR to the first transplant had a significant benefit from the second; among such patients, seven year rates of overall survival were 11 versus 43 percent for those in the single or double transplantation groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another randomized trial of single versus double HCT in 321 patients with newly diagnosed multiple myeloma found improved response rates with double HCT but no difference in overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/52\">",
"       52",
"      </a>",
"      ]. A subgroup analysis of the 160 patients who failed to achieve a near complete response after the first HCT revealed a nonsignificant trend towards improved overall survival with the second HCT with seven year overall survival rates of 60 versus 47 percent, respectively. This subgroup analysis was not powered to detect such a difference.",
"     </li>",
"     <li>",
"      A meta-analysis of six randomized controlled trials enrolling 1803 patients found that double HCT resulted in higher response rates and increased treatment-related mortality with no difference in overall survival for patients with MM as a whole [",
"      <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/54\">",
"       54",
"      </a>",
"      ]. However, it is still possible that a subgroup of patients might benefit from a double HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Awaiting the results of further trials, we suggest a second (tandem) HCT only for patients who do not have at least a VGPR with the first transplant.",
"   </p>",
"   <p>",
"    An example of this approach involves the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    for the first transplant and the same dose of melphalan or, less desirably, a lower dose melphalan (140",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    plus total body irradiation for the second transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/55\">",
"     55",
"    </a>",
"    ]. In a tandem transplant approach, the second transplant should be performed within six months after completion of the first [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Autologous versus allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some retrospective studies and one prospective study suggest that myeloablative allogeneic HCT is associated with significantly higher early mortality rates compared with autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/38,56\">",
"     38,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best shown in a prospective, multi-center trial in which patients with newly diagnosed multiple myeloma were randomly assigned to autologous HCT or combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, all patients up to the age of 55 who had matched-sibling donors were offered myeloablative allogeneic HCT. After an interim analysis, the option of allogeneic HCT was omitted for the remainder of the trial because 53 percent of the initial 36 patients who underwent allogeneic HCT died within the first three months. Among those who underwent allogeneic HCT, progression-free and overall survival appear to plateau from 5 to 10 years with rates of 22 and 39 percent, respectively. This plateau suggests that a small percentage of patients undergoing allogeneic HCT may be cured.",
"   </p>",
"   <p>",
"    Thus, although allogeneic HCT may be the only potentially curative treatment for multiple myeloma, initial treatment with high dose chemotherapy followed by allogeneic HCT is not commonly employed. This is due to many factors including the fact that a majority of patients are ineligible due to older age or comorbidities and because it is associated with high rates of overall mortality. Moreover the probability of cure is low, and remains unproven. We do not recommend myeloablative allogeneic HCT at this time due to the excessively high mortality rate and lack of proven benefit compared with autologous HCT.",
"   </p>",
"   <p>",
"    Both prospective and retrospective studies have evaluated the use of nonmyeloablative HCT in MM. Nonmyeloablative HCT relies primarily on a graft-versus-myeloma effect which is unfortunately often accompanied by the detrimental effects of graft-versus-host disease. Outcomes with this therapeutic approach have been mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to conflicting results, high treatment-related mortality, and toxicity, nonmyeloablative allogeneic HCT is not advised for patients with newly diagnosed myeloma outside of a clinical trial setting, except perhaps in those with high risk prognostic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of patients who are not transplant candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient is not a candidate for HCT, the only treatment option is chemotherapy alone (",
"    <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"     algorithm 2",
"    </a>",
"    ). The multiple treatment regimens available for this patient population are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF HIGH RISK MYELOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma who have t(14;16), t(14;20), or del17p13 are considered to have high risk disease. High risk MM accounts for approximately 15 percent of patients and is associated with a median survival of approximately two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/29/8666/abstract/17,18,20\">",
"     17,18,20",
"    </a>",
"    ]. Patients with high risk multiple myeloma should be considered for novel therapeutic strategies (ie, early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    containing regimens), since they do poorly with all conventional treatment options. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment options available for this patient population are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION AND MANAGEMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma frequently develop complications related to their disease, including hypercalcemia, renal insufficiency, infection, and skeletal lesions, which require specific treatment in addition to therapy directed at the malignant clone. Pneumococcal and influenza vaccine should also be given to all patients despite their suboptimal antibody response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/26/29090?source=see_link\">",
"       \"Patient information: Multiple myeloma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Verification of the diagnosis",
"      </strong>",
"      &mdash; Patients with multiple myeloma (MM) should be distinguished from patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) who do not need therapy (",
"      <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Multiple myeloma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with SMM, we recommend deferral of chemotherapy until disease progression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients who do not have end organ damage but have &ge;60 percent clonal plasma cells in the marrow have a median time to progression to symptomatic myeloma of seven months with end organ damage, and are also best considered to have MM requiring therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Smoldering (asymptomatic) multiple myeloma (SMM)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Multiple myeloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have end organ damage attributable to the underlying plasma cell disorder have MM and require therapy. The following findings, if attributable to the underlying plasma cell disorder, are clear indications for treatment: anemia, hypercalcemia, renal insufficiency, lytic bone lesions or severe osteopenia, and extramedullary plasmacytoma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Multiple myeloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with MM as defined above, we recommend prompt initiation of treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Risk stratification",
"      </strong>",
"      &mdash; Patients with MM are stratified at the time of diagnosis into three main risk categories (standard risk, intermediate risk, and high risk). This risk stratification has considerable prognostic value and also helps guide the selection of initial therapy. We recommend that at least one of the following tests, preferably FISH, be performed to assess risk in newly diagnosed patients (",
"      <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      FISH for detection of t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes",
"     </li>",
"     <li>",
"      Conventional cytogenetics (karyotyping) for detection of del 13, monosomy 13, or hypodiploidy",
"      <br/>",
"      <br/>",
"      Patients with t(14;16), t(14;20), or del17p13 by FISH are considered to have high risk myeloma. Patients with t(4;14) by FISH or deletion",
"      <span class=\"nowrap\">",
"       13/hypodiploidy",
"      </span>",
"      are considered to have intermediate risk MM. All other patients with MM who lack any of the high or intermediate risk cytogenetic abnormalities are considered to have standard risk MM; this includes patients with trisomies, t(11;14) and t(6;14). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Standard and intermediate risk myeloma",
"      </strong>",
"      &mdash; The main treatment options for standard and intermediate risk MM are chemotherapy alone or chemotherapy plus hematopoietic cell transplantation (HCT). Eligibility for HCT in MM varies across countries, and across institutions. Although guidelines are provided, the decision on transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Determining transplant eligibility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with standard or intermediate risk MM who are candidates for HCT, we recommend the use of induction therapy followed by autologous HCT rather than either conventional chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) or myeloablative allogeneic HCT (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). HCT is performed either early in the disease course or at the time of first relapse. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment of transplant candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients proceed with their first HCT after recovery from stem cell collection (early transplant) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ), although survival is similar between early versus delayed HCT, particularly in patients with standard risk myeloma. Timing of HCT is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H5#H5\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Timing of HCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Awaiting the results of further trials, we suggest a second (tandem) HCT only for patients who did not have at least a very good partial response to the first transplant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Double HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral stem cells are best collected before the patient is exposed to alkylating agents. As such, the preferred induction chemotherapy regimen may differ between patients who are candidates for autologous HCT (",
"      <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"       algorithm 1",
"      </a>",
"      ) and those who are not (",
"      <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"       algorithm 2",
"      </a>",
"      ). The multiple treatment regimens available for these patient populations are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link&amp;anchor=H3#H3\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\", section on 'Melphalan, prednisone, and thalidomide'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link&amp;anchor=H8888482#H8888482\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\", section on 'Our preferred approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       High risk myeloma",
"      </strong>",
"      &mdash; Patients with high risk MM should be encouraged to enroll in a clinical trial investigating novel therapeutic strategies, since they do poorly with all conventional treatment options. For patients who are not candidates for clinical trials or those who choose not to enroll in a clinical trial, potential options include the administration of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimen early in the disease course, with the addition of HCT for eligible patients not in complete response following initial therapy, and consideration of maintenance therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Complementary therapy",
"      </strong>",
"      &mdash; All patients with MM should be encouraged to be as active as possible in order to maintain bone density while avoiding activities with an excessive risk of trauma. Patients with one or more lesions on skeletal radiographs and those with osteopenia should be given bisphosphonate therapy, which significantly reduces the number of skeletal events. Pneumococcal and influenza vaccine should also be given to all patients. In addition, patients with MM frequently develop complications related to their disease, including hypercalcemia, renal insufficiency, infection, and skeletal lesions, which require specific treatment in addition to therapy directed at the malignant clone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"       \"The use of bisphosphonates in patients with multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"       \"Treatment of the complications of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/1\">",
"      Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/2\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/3\">",
"      Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/4\">",
"      Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/5\">",
"      Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/6\">",
"      Rago A, Grammatico S, Za T, et al. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Cancer 2012; 118:5544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/7\">",
"      Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol 2012; 9:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/8\">",
"      UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/9\">",
"      He Y, Wheatley K, Clark O, et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003; :CD004023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/10\">",
"      Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993; 50:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/11\">",
"      Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. Br J Cancer 1996; 73:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/12\">",
"      Mateos M, Lopez-Corral L, Hernandez M, et al. Smoldering multiple myeloma at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone as induction therapy followed by maintenance therapy with lenalidomide alone vs no treatment  (Abstract 991). Blood 2011; .:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/13\">",
"      Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/14\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/15\">",
"      Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/16\">",
"      Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/17\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/18\">",
"      Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/19\">",
"      Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/20\">",
"      Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/21\">",
"      Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/22\">",
"      Sirohi B, Powles R, Mehta J, et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999; 107:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/23\">",
"      Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007; 39:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/24\">",
"      Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/25\">",
"      Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/26\">",
"      Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008; 83:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/27\">",
"      Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/28\">",
"      Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/29\">",
"      Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007; 47:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/30\">",
"      Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/31\">",
"      Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran&ccedil;ais du My&eacute;lome. N Engl J Med 1996; 335:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/32\">",
"      Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/33\">",
"      Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du My&eacute;lome. Semin Hematol 2001; 38:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/34\">",
"      Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/35\">",
"      Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/36\">",
"      Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23:9227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/37\">",
"      Blad&eacute; J, Rosi&ntilde;ol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/38\">",
"      Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/39\">",
"      L&eacute;vy V, Katsahian S, Fermand JP, et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 2005; 84:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/40\">",
"      Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/41\">",
"      Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/42\">",
"      Lahuerta JJ, Grande C, Mart&iacute;nez-Lopez J, et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espa&ntilde;ol de S&iacute;ndromes Linfoproliferativos/Trasplante Aut&oacute;logo de M&eacute;dula Osea phase II trial. Br J Haematol 2003; 120:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/43\">",
"      Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/44\">",
"      Fassas AB, Barlogie B, Ward S, et al. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol 2003; 123:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/45\">",
"      Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/46\">",
"      Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/47\">",
"      Corso A, Mangiacavalli S, Barbarano L, et al. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged &lt;65 years. Cancer 2007; 109:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/48\">",
"      Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (&gt; or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/49\">",
"      Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/50\">",
"      Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/51\">",
"      Stadtmauer EA. Multiple myeloma, 2004--one or two transplants? N Engl J Med 2003; 349:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/52\">",
"      Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/53\">",
"      Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012; 10:CD004626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/54\">",
"      Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/55\">",
"      Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/29/8666/abstract/56\">",
"      Bj&ouml;rkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88:4711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6643 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8666=[""].join("\n");
var outline_f8_29_8666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1062479\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VERIFICATION OF THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1899117\">",
"      Monoclonal gammopathy of undetermined significance (MGUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Smoldering (asymptomatic) multiple myeloma (SMM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2601852\">",
"      High risk myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2601859\">",
"      Intermediate risk myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2601866\">",
"      Standard risk myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DETERMINING TRANSPLANT ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Age and disease stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20047776\">",
"      TREATMENT OF STANDARD OR INTERMEDIATE RISK MYELOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of transplant candidates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Autologous HCT versus chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Double HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Autologous versus allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of patients who are not transplant candidates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF HIGH RISK MYELOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION AND MANAGEMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6643|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/52/12111\" title=\"algorithm 1\">",
"      Therapy approach MM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/59/25534\" title=\"algorithm 2\">",
"      Therapy approach MM II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6643|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/46/40685\" title=\"figure 1\">",
"      BMT in untreated myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42603\" title=\"table 1\">",
"      Diagnostic criteria for myeloma MGUS and SMM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25099\" title=\"table 2\">",
"      Risk stratification of myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 3\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/26/29090?source=related_link\">",
"      Patient information: Multiple myeloma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10618?source=related_link\">",
"      Staging and prognostic studies in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_29_8667="WHO IGCTs";
var content_f8_29_8667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization classification of intracranial germ cell tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Germinomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       <strong>",
"        Nongerminomatous germ cell tumors",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Embryonal carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yolk sac tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Choriocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Teratoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bening teratomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Immature*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Mature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Teratoma with malignant transformation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mixed germ cell tumors",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May contain rare malignant germ cell elements.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Louis DN, Ohgaki H, Wiesterl O, et al. World Health Organization Classification of Tumours of the Central Nervous System, 3rd Edition, IARC Press, Lyon, 2007.Copyright &copy; 2007 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8667=[""].join("\n");
var outline_f8_29_8667=null;
var title_f8_29_8668="Metastasis free survival in STS";
var content_f8_29_8668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year metastasis-free rate according to grade in 1240 adults with different histologic types of soft tissue sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histologic types",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant fibrous histiocytoma",
"       </td>",
"       <td>",
"        90 percent (n = 33)",
"       </td>",
"       <td>",
"        77 percent (n = 160)",
"       </td>",
"       <td>",
"        48 percent (n = 156)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposarcoma",
"       </td>",
"       <td>",
"        94 percent (n = 85)",
"       </td>",
"       <td>",
"        72 percent (n = 71)",
"       </td>",
"       <td>",
"        59 percent (n = 32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiomyosarcoma",
"       </td>",
"       <td>",
"        93 percent (n = 16)",
"       </td>",
"       <td>",
"        67 percent (n = 65)",
"       </td>",
"       <td>",
"        45 percent (n = 67)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPNST",
"       </td>",
"       <td>",
"        78 percent (n = 5)",
"       </td>",
"       <td>",
"        56 percent (n = 26)",
"       </td>",
"       <td>",
"        52 percent (n = 41)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial sarcoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        75 percent (n = 69)",
"       </td>",
"       <td>",
"        35 percent (n = 56)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyosarcoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        75 percent (n = 45)",
"       </td>",
"       <td>",
"        42 percent (n = 15)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unclassified sarcoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        70 percent (n = 43)",
"       </td>",
"       <td>",
"        40 percent (n = 97)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        82 percent (n = 18)",
"       </td>",
"       <td>",
"        69 percent (n = 75)",
"       </td>",
"       <td>",
"        37 percent (n = 65)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MPNST: malignant peripheral nerve sheath tumor.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Coindre JM, et al. Cancer 2001; 91:1914.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8668=[""].join("\n");
var outline_f8_29_8668=null;
var title_f8_29_8669="ELF elastase with aerosol AAT";
var content_f8_29_8669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of aerosolized alpha-1 antitrypsin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of aerosolized alpha-1 antitrypsin (100 mg every 12 hours) on epithelial lining fluid (ELF) antineutrophil elastase capacity. Replacement therapy raised ELF antielastase capacity into the normal range. The linear relationship between days 1 and 7 is illustrative and not necessarily representative of the real changes that occurred.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hubbard, RC, Brantly, ML, Sellers, SE, et al, Ann Intern Med 1989; 111:206.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_29_8669=[""].join("\n");
var outline_f8_29_8669=null;
var title_f8_29_8670="Contents: Primary care ophthalmology";
var content_f8_29_8670=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care ophthalmology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care ophthalmology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6986\">",
"           Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26074\">",
"           Age-related macular degeneration: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9063\">",
"           Angle-closure glaucoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/16/26888\">",
"           Approach to the adult with acute persistent visual loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/38/19048\">",
"           Blepharitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/19/2362\">",
"           Cataract in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36023\">",
"           Classification and clinical features of diabetic retinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29128\">",
"           Complications of contact lenses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34600\">",
"           Corneal abrasions and corneal foreign bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/11/25784\">",
"           Dry eyes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4088\">",
"           Eyelid lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/12/33992\">",
"           Herpes simplex keratitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42457\">",
"           Laser refractive surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34855\">",
"           Open-angle glaucoma: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/48/18183\">",
"           Overview of contact lenses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15396\">",
"           Photokeratitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/38/32362\">",
"           Prevention and treatment of diabetic retinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41879\">",
"           Pterygium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36504\">",
"           Retinal detachment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/13/4311\">",
"           Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38743\">",
"           Retinal vein occlusion: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/27/19896\">",
"           Retinitis pigmentosa: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17239\">",
"           Retinitis pigmentosa: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/16/23817\">",
"           Uveitis: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/10/10407\">",
"           Uveitis: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2329\">",
"           Visual impairment in adults: Refractive disorders and presbyopia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-52A7ABAB1B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_29_8670=[""].join("\n");
var outline_f8_29_8670=null;
var title_f8_29_8671="Contents: Noninvasive cardiac imaging";
var content_f8_29_8671=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Noninvasive cardiac imaging",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Noninvasive cardiac imaging",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Echocardiography",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/53/13145\">",
"           Contrast echocardiography: Clinical applications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/49/23318\">",
"           Contrast echocardiography: Contrast agents, safety, and imaging technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15656\">",
"           Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/60/33735\">",
"           Echocardiographic evaluation of left ventricular diastolic function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/18/6438\">",
"           Echocardiographic evaluation of prosthetic heart valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1082\">",
"           Echocardiographic evaluation of the aortic valve",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31528\">",
"           Echocardiographic evaluation of the atria and appendages",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/41/32409\">",
"           Echocardiographic evaluation of the mitral valve",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27077\">",
"           Echocardiographic evaluation of the pericardium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20567\">",
"           Echocardiographic evaluation of the pulmonic valve and pulmonary artery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/7/27766\">",
"           Echocardiographic evaluation of the right ventricle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/44/10952\">",
"           Echocardiographic evaluation of the thoracic and proximal abdominal aorta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/2/14378\">",
"           Echocardiographic evaluation of the tricuspid valve",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3096\">",
"           Echocardiographic evaluation of ventricular septal defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15562\">",
"           Echocardiographic recognition of cardiomyopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4662\">",
"           Echocardiography essentials: Physics and instrumentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/4/12361\">",
"           Echocardiography in detection of intracardiac sources of embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/40/18054\">",
"           Hemodynamics derived from transesophageal echocardiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/0/15365\">",
"           Principles of Doppler echocardiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35319\">",
"           Protocols for stress echocardiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/6/11369\">",
"           Role of echocardiography in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2856\">",
"           Role of echocardiography in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/8/20617\">",
"           Role of echocardiography in infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/42/20138\">",
"           Role of stress testing after coronary revascularization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27466\">",
"           Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/5/41048\">",
"           Stress echocardiography: Indications, imaging techniques and safety",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28743\">",
"           Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23146\">",
"           Three-dimensional echocardiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7897\">",
"           Tissue Doppler echocardiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/39/35445\">",
"           Transesophageal echocardiography in the evaluation of aortic valve disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/3/42040\">",
"           Transesophageal echocardiography in the evaluation of mitral valve disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/59/13240\">",
"           Transesophageal echocardiography in the evaluation of the left ventricle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/8/31878\">",
"           Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/24/38280\">",
"           Transesophageal echocardiography: Indications, complications, and normal views",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24342\">",
"           Transthoracic echocardiography for the evaluation of chest pain in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/53/14167\">",
"           Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         MRI/CT",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/3/34874\">",
"           Clinical utility of cardiovascular magnetic resonance imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30410\">",
"           Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20906\">",
"           Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11610\">",
"           Noninvasive methods for measurement of left ventricular systolic function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/35/5689\">",
"           Principles of magnetic resonance imaging",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multimodality imaging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/56/29578\">",
"           Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11610\">",
"           Noninvasive methods for measurement of left ventricular systolic function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/2/14376\">",
"           Radiation dose and risk of malignancy from cardiovascular imaging",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Perfusion imaging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3496\">",
"           Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23066\">",
"           Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35192\">",
"           Basic properties of myocardial perfusion agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/9/42134\">",
"           Dobutamine stress radionuclide myocardial perfusion imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24970\">",
"           Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19946\">",
"           Impact of medications and methylxanthines on stress testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11610\">",
"           Noninvasive methods for measurement of left ventricular systolic function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/33/6678\">",
"           Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/6/11369\">",
"           Role of echocardiography in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/42/20138\">",
"           Role of stress testing after coronary revascularization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28743\">",
"           Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43081\">",
"           Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10330\">",
"           Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C05A1ED7ED-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_29_8671=[""].join("\n");
var outline_f8_29_8671=null;
